Category Archives: Embryonic Stem Cells


The very interesting life of the Hydractinia – Jill Lopez

A little-known ocean-dwelling creature most commonly found growing on dead hermit crab shells may sound like an unlikely study subject for researchers, but this animal has a rare ability -- it can make eggs and sperm for the duration of its lifetime. This animal, calledHydractinia, does so because it produces germ cells, which are precursors to eggs and sperm, nonstop throughout its life. Studying this unique ability could provide insight into the development of human reproductive system and the formation of reproductive-based conditions and diseases in humans.

"By sequencing and studying the genomes of simpler organisms that are easier to manipulate in the lab, we have been able to tease out important insights regarding the biology underlying germ cell fate determination -- knowledge that may ultimately help us better understand the processes underlying reproductive disorders in humans," Dr. Andy Baxevanis, director of the National Human Genome Research Institute's (NHGRI) Computational Genomics Unit and co-author of the paper. NHGRI is part of the National Institutes of Health.

In a study published in the journalScience, collaborators at NHGRI, the National University of Ireland, Galway, and the Whitney Laboratory for Marine Bioscience at the University of Florida, Augustine, reported that activation of the geneTfap2in adult stem cells inHydractiniacan turn those cells into germ cells in a cycle that can repeat endlessly.

In comparison, humans and most other mammals generate a specific number of germ cells only once in their lifetime. Therefore, for such species, eggs and sperm from the predetermined number of germ cells may be formed over a long period of time, but their amount is restricted. An international team of researchers have been studyingHydractinia's genome to understand how it comes by this special reproductive ability.

Hydractinialives in colonies and is closely related to jellyfish and corals. AlthoughHydractiniais dissimilar to humans physiologically, its genome contains a surprisingly large number of genes that are like human disease genes, making it a useful animal model for studying questions related to human biology and health.

Hydractiniacolonies possess feeding polyps and sexual polyps as a part of their anatomy. The specialized sexual polyps produce eggs and sperm, making them functionally similar to gonads in species like humans.

During human embryonic development, a small pool of germ cells that will eventually become gametes is set aside, and all sperm or eggs that humans produce during their lives are the descendants of those original few germ cells. Loss of these germ cells for any reason results in sterility, as humans do not have the ability to replenish their original pool of germ cells.

In a separate study, Dr. Baxevanis at NHGRI and Dr. Christine Schnitzler at the Whitney Lab have completed the first-ever sequencing of theHydractiniagenome. In this study, researchers used this information to scrutinize the organism's genome for clues as to why there are such marked differences in reproductive capacity between one of our most distant animal relatives and ourselves.

"Having this kind of high-quality, whole-genome sequence data in hand allowed us to quickly narrow down the search for the specific gene or genes that tellHydractinia's stem cells to become germ cells," said Dr. Baxevanis.

The researchers compared the behavior of genes in the feeding and sexual structures ofHydractinia. They found that theTfap2gene was much more active in the sexual polyps than in the feeding polyps in both males and females. This was a clue that the gene might be important in generating germ cells.

The scientists next confirmed thatTfap2was indeed the switch that controls the process of perpetual germ cell production. The researchers used the CRISPR-Cas9 gene-editing technique to removeTfap2fromHydractiniaand measured the resulting effects on germ cell production. They found that removingTfap2fromHydractiniastops germ cells from forming, bolstering the theory thatTfap2controls the process.

The researchers also wanted to know ifTfap2was influencing specific cells to turn into germ cells. Their analysis revealed thatTfap2only causes adult stem cells inHydractiniato turn into germ cells.

Interestingly, theTfap2gene also regulates germ cell production in humans, in addition to its involvement in myriad other processes. However, in humans, the germ cells are separated from non-germ cells early in development. Still, despite the vast evolutionary distance betweenHydractiniaand humans, both share a key gene that changes stem cells into germ cells.

Read the original here:
The very interesting life of the Hydractinia - Jill Lopez

Intrinsic disorder controls two functionally distinct dimers of the master transcription factor PU.1 – Science Advances

INTRODUCTION

Eukaryotic transcription factors are highly enriched in intrinsically disordered regions (IDR), which are sequences that do not adopt a stably structured conformation but are nevertheless essential for activity. Compared with only ~5% in prokaryotes and archaea, more than 80% of eukaryotic transcription factors have extended IDRs (1). In the unicellular bakers yeast (Saccharomyces), transcription factors comprise the most prodigious functional category of disorder-encoding proteins (2). In multicellular organisms, ~50% of all residues in eukaryotic factors from model animals (humans, Drosophila) and plants (Arabidopsis) map to disordered regions (3). Clearly, IDRs constitute a major component in eukaryotic gene regulation, and it is therefore important to define their contributions to the molecular properties of transcriptional factors.

While IDRs are generally diverse in sequence, charge characteristics confer specific properties to transcription factor IDRs. For example, positively charged tails mediate diffusion along DNA (4) and ubiquitination by E3 ligases of several transcription factors, notably p53 (5). More common, however, are negatively charged (acidic) IDRs such as transactivation domains, which recruit basal factors such as TFIIB and TATA binding protein to the promoter (6, 7), and signaling moieties such as PEST domains that are rich in Glu and Asp residues (8, 9). While IDRs exhibit sequence-dependent conformational preferences on their own, these preferences are also modified by folded domains to which they are tethered (10). In transcription factors, IDRs are highly enriched around DNA binding domains (DBDs) (11), which display electrostatically biased surfaces to their surroundings. Their DNA contact surfaces are typically rich in positively charged residues while exposing neutral or even negatively charged residues elsewhere. Because DBDs alone represent an incomplete context in functional regulation, our aim is to elaborate the mechanism by which charged, particularly acidic IDRs regulate the recognition of tethered DBDs with each other as well as with target DNA.

As a model system for understanding the impact of intrinsically disordered tethers in transcription factors, the ETS family protein PU.1 exemplifies the most common (known as type I) configuration (3), in which its eponymous DBD of ~90 residues comprises the only well-folded structure. The remaining ~170 and 12 residues that flank N- and C-terminally, respectively, are intrinsically disordered sequences. The extended N-terminal IDR consists of an acidic transactivation domain (human residues 1 to 80), a Q-rich domain (residues 81 to 116), and a highly negatively charged PEST domain (residues 117 to 165), all of which are characteristic disordered regions in eukaryotic factors (9). This domain architecture, conserved among PU.1 orthologs, commends PU.1 as an ideal model from which more complex transcription factor architectures may be approached.

In addition to the canonical attributes representative of eukaryotic transcription factors, PU.1 is also specifically required for life. During hematopoiesis, all circulating blood cells are ultimately derived from a small population of self-renewing stem cells. PU.1 is a master regulator that is required for the renewal of the hematopoietic stem cells (12) and, in collaboration with other factors, directs their differentiation to every major myeloid and lymphoid lineage. Aberrant PU.1 activity is associated with lymphomas (13), myeloma (14), leukemias (15), and Alzheimers disease (16). Most recently, PU.1 was also identified as the key trigger for tissue fibrosis (17). Genetic and pharmacologic interventions targeted at PU.1 have established its therapeutic potential in acute myeloid leukemia (18, 19) and fibrotic diseases (17). Mechanisms that govern the molecular interactions of PU.1 are therefore relevant to developmental genetics and multiple therapeutic areas including hematology/oncology, immunology, neurology, and rheumatology.

Despite its biological significance, detailed knowledge of the molecular properties of PU.1 has been limited to its structured ETS domain. PU.1 therefore exemplifies the incomplete context problem in structural biology, which we have now tackled by addressing the role of the N- and C-terminal IDRs in the behavior of the ETS domain. The data reveal that these tethered IDRs critically control the propensities of the ETS domain to form discrete dimers with and without cognate DNA. These dimeric states, which are conformationally distinct, establish a novel regulatory mechanism that enables negative feedback in PU.1 transactivation. In addition to implications on PU.1 autoregulation in vivo, these results address a general class of problems in which negatively charged IDRs, which are abundant in transcription factors as transactivation and other functional domains, exert direct functional control at the protein/DNA level.

The DNA binding (ETS) domain of PU.1 represents its only structured domain, whose 1:1 complex with cognate DNA (Fig. 1A) is structurally conserved in this family of transcription factors. However, in contrast with other ETS members, the ETS domain of PU.1 (N165) forms 2:1 complexes at single DNA cognate sites in biophysical assays (20, 21). Measurements of self-diffusion by protein-observed diffusion ordered spectroscopy (DOSY) nuclear magnetic resonance (NMR) showed that inclusion of the N-terminal PEST domain (N117) maintained the DNA binding modes accessible to the ETS domain (Fig. 1B). Specifically, DOSY titrations of both N117 and N165 with DNA oligomers harboring a single cognate binding site showed two distinct bound states, with the minima in diffusion coefficient occurring sharply at a DNA:protein ratio of 0.5, corresponding to a 2:1 complex. The single minima at DNA:protein = 0.5 excluded the formal possibility of a 2:2 complex or nonspecific binding. If PU.1 were binding DNA nonspecifically beyond the 1:1 complex at equilibrium (i.e., in an unsaturable manner proportional to the concentration of free protein), then the minima in diffusion coefficient would occur at the lowest DNA:protein ratios where protein would be at greatest excess relative to DNA. Independently, protein-into-DNA titrations showed that N117 enhanced the affinity of the 1:1 complex (KD1) by more than twofold and reduced the affinity of the 2:1 complex (KD2) relative to N165 by about fourfold (Fig. 1B). Taking the ratio KD2/KD1 as an index of cooperativity in DNA binding, 2:1 complex formation by N117 was therefore more negatively cooperative than N165. The PEST domain, therefore, preserved the intrinsic binding modes of the ETS domain of PU.1, namely, a 1:1 and 2:1 complex with cognate DNA, while modulating their affinities in solution.

(A) The ETS domain (N165) is the only structured and minimal DNA binding unit (PDB: 1PUE). (B) Left: DOSY NMR titrations of N117 and N165 with cognate DNA yielding equivalence points at DNA:protein = 0.5 and 1.0, corresponding to 2:1 and 1:1 complexes, respectively. The absence of single global minima at DNA:protein = 1:1 formally excludes the possibility of a 2:2 complex. Right: Fluorescence anisotropy titrations with labeled cognate DNA. Both N117 and N165 form a 2:1 complex at a single DNA site with different negative cooperativity as defined by the ratio of the two sequential dissociation constants KD1 and KD2 (dashed lines; see Materials and Methods). Parametric values are given in table S1. (C) Scheme of negative feedback in PU.1 trans-regulation. A mechanistic link between dimerization and negative feedback predicts a reduction in PU.1 activity under conditions permissive of an inactive 2:1 complex. (D) Synthetic PU.1-dependent EGFP reporters. A minimal TATA box was driven by enhancers composed only of tandem EBS (yellow blocks) spaced 20 bp apart. Hatched blocks represent mutated sites. (E) Representative flow cytometric data of untreated HEK293 cells and upon transfection with a constant dose of the 5EBS reporter and/or up to 25 ng of an expression plasmid encoding full-length PU.1 (see Materials and Methods). Quadrant Q2 contained the EGFP-positive cells to be counted out of all PU.1-expressing cells (Q2 + Q3). (F) EGFP fluorescence in Q2 taken over the summed fluorescence in Q2 + Q3 at 24 hours after cotransfection of the EGFP reporter plasmid and the indicated dose of PU.1 expression plasmid. Each data point represents the means SE of triplicate or more samples. (G) RT-PCR measurements of pu.1, csf1ra, and e2f1 mRNA abundance (relative to gapdh) in THP-1 cells induced with PMA following exposure to either doses of a PU.1 inhibitor for 2 hours (left) or a fixed dose of 20 M inhibitor for various periods (right). Cells were visualized at 40 magnification after Giemsa staining.

In tissues that natively express PU.1, such as macrophages, PU.1 activity is highly inducible (22). The 1:1 complex formed by ETS domains represents the established trans-regulatory complex for ETS transcription factors. Little is understood about the functional nature of the 2:1 complex, for which no ETS analog is known, although its negative cooperative relationship with the 1:1 complex suggests an inactive species (Fig. 1C). To solve this puzzle, we measured PU.1 transactivation in cells using an enhanced green fluorescent protein (EGFP) reporter gene under the control of various synthetic enhancer elements consisting only of tandem copies of the B motif (Fig. 1D), a PU.1-specific ETS binding site (EBS) derived from the lymphoid Ig2-4 enhancer (GenBank X54550). Each consecutive site was spaced by 20 base pairs (bp), or two helical turns, such that bound proteins were arrayed on the same helical face to facilitate the recruitment of the transcriptional machinery. In addition, as the 2:1 complex was known to require an extended site size relative to the monomer (20), presenting the bound protein along one helical face would amplify site-site interactions and DNA perturbations, thus rendering most manifest the functional effects of the 2:1 complex.

When transiently transfected into PU.1-negative human embryonic kidney (HEK) 293 cells, the reporters were negligibly activated by endogenous transcription factors, including other ETS family proteins (Fig. 1E). Cotransfection of an expression plasmid encoding full-length PU.1, which was independently tracked by a cotranslating infrared fluorescent protein (iRFP) marker, yielded EGFP fluorescence in a dose-dependent manner. We established a dosing range for the PU.1 expression plasmid that gave a linear variation in PU.1 abundance in HEK293 cells within the physiologically inducible range found in PU.1-expressing myeloid cells (fig. S1). In this configuration, PU.1-dependent transactivation was quantified as the fraction of iRFP-positive cells that were also EGFP positive (Fig. 1E). The functional outcome of an inactive, negatively cooperative 2:1 complex would be a bell-shaped reporter dose-response as the enhancer, which varied in density and spacing of EBS (i.e., cis-regulatory syntax), became saturated with nonproductively (2:1) bound PU.1. In the alternative, the reporter signal would dose-dependently settle to a saturable level, depending on the level at which the 2:1 complex retained activity relative to the 1:1 complex. The synthetic B reporters were therefore well suited to interrogate cellular PU.1 activity, free from the requirement or interference from other promoter-specific cofactors, at the protein/DNA level.

At equivalent PU.1 doses, all enhancer configurations showed graded reporter expression in step with the density of EBS at each enhancer (Fig. 1F). This was consistent with an expected multivalent effect with respect to PU.1 binding sites. However, EGFP expression increased monotonically only with enhancers harboring tandem 3 and 5 EBS. Upon peaking at intermediate PU.1 doses, the 1 and 2 enhancers were repressed by further increases in PU.1. To determine whether the reversal in transactivation involved PU.1 interactions at the enhancer, we mutated the even-numbered sites in the 5EBS reporter to generate a 3EBS variant in which the cognate sites doubled in spacing (Fig. 1D). The resultant 3-alt-EBS reporter exhibited lower transactivation than the more densely spaced 3EBS, and its reporter signal also no longer increased monotonically (Fig. 1F). The spacing effect, therefore, demonstrated that the functional reversal could not be due solely to PU.1 interactions away from the DNA, which would be inert to syntax changes at the DNA. The observation of bell-shaped dose response for the 1 and 2 enhancers, but not the 3 or 5EBS enhancers, suggested additive perturbations of the local DNA structure, which were amplified by the helical spacing of the sites. This interpretation was supported by previous DNA footprinting of the PU.1 ETS domain, which showed strong differences between the singly and doubly PU.1-bound DNA (20). Alternatively, binding at the higher-density sites might exhaust a required co-repressing factor for the 2:1 complex. However, this possibility was discounted by the different dose responses exhibited by the 3EBS and 3-alt-EBS, which had the same site density, and the occurrence in a cell line (HEK293) that does not natively use PU.1 in gene regulation. Because net transactivation activity was reduced under conditions corresponding to population of the 2:1 complex, the evidence suggested that the 2:1 complex lost activity relative to the 1:1 complex. Thus, manipulation of enhancer syntax (density and spacing) demonstrated negative feedback in PU.1 transactivation in a manner consistent with self-titration of the transcriptionally active 1:1 complex by an inactive dimer bound to DNA.

To extend our functional results to a more physiologic context, we evaluated the impact of graded PU.1 inhibition on three PU.1 target genes in THP-1 cells, a widely used human monocyte/macrophage model. Cells were treated with a PU.1 inhibitor (fig. S2), as a function of dose or incubation period, before stimulation with phorbol 12-myristate 13-acetate (PMA) to mimic PU.1 induction during myeloid differentiation. As PU.1 targets, we examined the pu.1 (Spi-1) gene itself, which is autoregulated (23); csf1ra, a PU.1 target that encodes the subunit of the colony-stimulating factor receptor; and e2f1, which is negatively regulated by PU.1 (24). We first tested the effect of dose-dependent inhibition of PU.1 for a fixed period of 2 hours on the transcription of these genes by reverse transcription polymerase chain reaction (RT-PCR) (table S2). Expression of pu.1 and csf1ra, both positively regulated PU.1 targets, was increased by lower doses of inhibitor before marked reduction to ~50% at higher doses, yielding bell-shaped profiles (Fig. 1G). In the case of negatively regulated e2f1, expression was further inhibited across the dosage range of inhibitor tested. Trans-regulation of all three genes upon dose-dependent inhibition of PU.1 was consistent with an increase in PU.1 activity associated with the relief of negative feedback.

To assess the impact of PU.1 inhibition temporally, we tested a fixed dose of inhibitor (20 M) over time, up to 16 hours before PMA induction. While PU.1 expression gave a bell-shaped dose response at 2 hours of inhibitor exposure, continued exposure at an intermediate (derepressing) dose became strictly inhibitory (Fig. 1G). In contrast, derepression in csf1ra expression continued for 8 hours. Expression of the negative-regulated e2f1 gene, which was dose-dependently reduced at 2 hours of PU.1 inhibition, began to increase by 8 hours of inhibitor exposure. These results thus demonstrated a dynamic nature to the negative feedback that corresponded to the specific effect of PU.1 on the target gene (peaks in activated genes or troughs in repressed genes). The opposing behavior of csf1ra and e2f1 expression, in accordance to their opposite dependence on PU.1, supported the physiologic relevance of PU.1 negative feedback. Last, the latency exhibited by the two target genes relative to the autoregulated pu.1 gene suggested a combined effect between changes in PU.1 availability at the expression level and competition for binding at the DNA level.

In summary, the expression profiles of pu.1, csf1ra, and e2f1 showed that graded PU.1 inhibition led to nonmonotonic changes in trans-regulatory activity in a manner consistent with derepression of negative feedback. Together with the dependence of the synthetic B reporter on PU.1 dose and enhancer syntax (site density and spacing), the data support the biophysically observed 2:1 complex as a functionally relevant species in the cell and motivate specific interest in how the ETS domain dimerizes in its native structural context.

Comparison of DNA binding by N117 and N165 shows that the N-terminally tethered PEST domain enhanced the affinity of the 1:1 complex but reduced the affinity of the 2:1 complex (Fig. 1B). To better understand the influence of the PEST domain on DNA recognition by PU.1, we first established whether the PEST domain was disordered in the cognate complex by comparing the 1H-15N heteronuclear single quantum coherence spectroscopy (HSQC) fingerprint region of DNA-bound N165 and N117 (Fig. 2A). As with N165 (20), the unbound and 1:1 complex gave well-dispersed spectra, while >80% of the cross peaks for 2:1-bound N117 were broadened out (fig. S3). The similar behavior by the two constructs indicated that broadening was not due to the larger size of the 2:1 complex, in which case broadening would be exacerbated for N117. In 1:1-bound N165, whose resonances were well resolved, 88 of the 95 assigned residues overlapped with N117, with all PEST residues clustered around 8.2 0.2 parts per million (ppm) on the 1H dimension, a chemical shift characteristic of disordered structures. Because this region also represented the residues that were detected in HSQC of the 2:1 complex (fig. S3), the evidence suggested similar changes in the chemical environment for the structured ETS domain (represented by the dispersed resonances in intermediate exchange) between free and DNA-bound states of N117 and N165. Thus, the local structure of the ETS domain was not altered upon DNA binding by the flanking residues, and the PEST domain behaved as a disordered tether in the ETS/DNA complex.

(A) 1H-15N HSQC of N117 and N165 in the 1:1 complex with cognate DNA. Assignment of the N165 spectrum was 90% complete. (B) DNA binding by N165 and N117 in 0.1 M and 0.05 M NaCl, showing the impact of the PEST domain on the cooperativity of 2:1 complex formation. Parametric values of the equilibrium dissociation constants are given in table S1.

Ligand binding to DNA is generally sensitive to electrostatic interactions. To better understand the impact of the disordered PEST domain on 2:1 complex formation, we probed the electrostatic contribution to site-specific binding by N165 and N117 (Fig. 2B). Reducing Na+ concentration from 0.15 M (as shown in Fig. 1B) to 0.10 M did not affect 2:1 binding by N117. However, the biphasic binding indicative of strongly negatively cooperative formation of the 2:1 complex for N165 was abolished as the anisotropy values showed. A further reduction to 0.05 M salt resulted in monophasic transitions to the 2:1 complex by both constructs. Notably, binding weakened with decreasing Na+ concentration and therefore could not reflect simple electrostatic effects on DNA binding. These observations indicated that additional unbound species must regulate DNA recognition by PU.1 and that these species were salt sensitive and controlled by the disordered PEST domain.

The isolated ETS domain, N165, forms a feeble dimer without DNA, as judged by heteronuclear NMR (25) as well as static and dynamic light scattering (21). To determine the role of the disordered PEST domain in PU.1 dimerization without DNA, we examined several hydrodynamic parameters, which are highly sensitive to self-association, of N117 as a function of concentration (Fig. 3A). DOSY NMR spectroscopy revealed a marked concentration dependence for the apparent diffusion coefficient. The profile was described by a two-state monomer-dimer equilibrium (detailed in Materials and Methods) with a dissociation constant below 10 M (table S1). To assess concentrations below 50 M, which was limiting for NMR, we performed intrinsic Trp fluorescence anisotropy measurements, which is sensitive to rotational diffusion. N117 exhibited a substantial change in steady-state anisotropy that was also described by a two-state dimer with a dissociation constant at below 10 M. In contrast, N165 showed no change. The localization of the three Trp residues in the structured ETS domain of both constructs represented further evidence that the concentration-dependent changes in N117 involved the ETS domain. Last, high-precision densimetry showed a concentration-dependent transition by N117 that was again described by two-state dimerization. (Because density varies directly with concentration, density-detected transitions sit on sloped baselines as opposed to the flat baselines in spectrometric titrations.) Relative to the diffusion probes, the densimetric titration gave a higher dissociation constant, 35 15 M. As a control, N165 gave a concentration-independent partial specific volume (from the slope, see Materials and Methods) of 0.77 0.01 ml/g, a value characteristic of structured globular proteins. Multiple orthogonal probes therefore described a reversible N117 dimer that was considerably more avid than N165.

(A) Concentration-dependent changes in hydrodynamic and volumetric properties by DOSY NMR, intrinsic Trp fluorescence anisotropy, and high-precision densimetry of N117 in 0.15 M Na+ at 25C. Red curves represent fits of the data to a two-state monomer-dimer transition. (B) Representative zero-charge ESI mass spectra of N117 at 13 and 840 M total concentration, normalized to the height of the monomer (17 kDa) peak. The ratios of the integrated dimer-to-monomer intensities (molecular weight shown) were French-curved to guide the eye. (C) Far-UV CD spectra of N117 and N165 at 25 M, plotted on a per-molecule basis to highlight the contribution of the N-terminal residues. (D) Concentration-dependent, per-residue spectra of N117 and N165 (left). Dimerization as revealed by singular value decomposition of the N117 spectra and fitted to a two-state transition. (E) 1H-15N HSQC of 400 M N117 and N165 at 0.15 NaCl. Under these conditions, N117 was predominantly dimeric and N165 was monomeric. The assignments shown are for N117. Inset: {1H}15N-NOE for N117 and N165.

We pause to note that concentration dependence of the equilibrium constant (and melting temperatures) rules out monomolecular interactions, such as conformational changes without association. Local conformational changes can and do produce changes in diffusion and volumetric parameters, but this behavior without an intermolecular component cannot depend on total concentration at thermodynamic equilibrium. Artefacts such as aggregation during the experiments are unlikely based on the linear posttransition baselines for all three probes (DOSY NMR, fluorescence anisotropy, and density). Independent evaluation of purified N117 by SDSpolyacrylamide gel electrophoresis (PAGE) and mass spectrometry (MS) (fig. S4) also confirmed the absence of detectable contamination and aggregation. At a deeper level of analysis, the two-state self-association model, given by Eq. 7 in Materials and Methods that fitted the titration data in Fig. 3A, is an nth-order polynomial, where n is the stoichiometry of the oligomer. The value of n (= 2 for dimer), which is fixed in the fitting, imposes a severe constraint on the shape of the titration to which the model may adequately fit. As detailed elsewhere (26), oligomers n 3 invariably show sigmoidal (S-shaped) transitions. Only a two-state dimer exhibits nonsigmoidal profiles on linear concentration scales, precisely as constructed in Fig. 3A and observed in the data. On this basis, the biophysical evidence is unambiguous in showing homodimerization of PU.1 without DNA, and the range of dissociation constants yielded by the different probes reflected the distinct molecular properties they sampled.

To further strengthen this evidence, we resolved N117 by electrospray ionization (ESI)MS up to a concentration of 840 M. Using an established maximum entropy procedure (27), peaks corresponding to both monomeric and dimeric PU.1 were observed in deconvoluted zero-charge mass spectra (Fig. 3B). The integrated intensities of the two species were quantitative, but they did not correspond to solution conditions in the other experiments. This was due to the techniques requirement for a volatile buffer (NH4HCO3), species-dependent ionization efficiency, and the potential for ionization-induced dissociation of the complex. Notwithstanding, the ratio of dimer-to-monomer intensities varied in favor of the dimeric species with increasing total protein concentration (Fig. 3B, bottom). The concentration dependence excluded the possibility that either species could represent a static contaminant but rather corresponded to a N117 monomer and dimer at dynamic equilibrium.

To gain insight into the conformational structure of the free PU.1 dimer, we interrogated N165 and N117 by circular dichroism (CD) and NMR spectroscopy. At an identically low concentration (25 M), a net contribution of coil content due to the PEST domain was apparent (Fig. 3C). With increasing concentration, N165 showed a spectral shift but without an endpoint at 300 M. In contrast, the corresponding spectra for N117 (weighted by contributions from the disordered PEST domain) underwent a nonsigmoidal transition that, unlike N165, was substantially completed at 300 M (Fig. 3D). Model fitting of the farultraviolet (UV) CD spectra, which are sensitive to secondary structure content, to a two-state dimer yielded a dissociation constant of K2 = 46 19 M. As an analysis of full CD spectra by singular value decomposition rendered more structural information than the other titration probes in Fig. 3A, we will use the CD-fitted K2 for comparison with other PU.1 constructs and solution conditions.

To probe the local structure of the PU.1 dimer, we compared the 1H-15N HSQC fingerprint of 400 M N117 and N165, concentrations at which the preceding experiments showed that N117 was predominantly dimeric, while N165 remained monomeric (Fig. 3E; compare to Fig. 3A). Dispersed cross-peaks for the two constructs mostly overlapped within experimental uncertainty (inset). PEST domain residues were clustered at 8.2 0.2 ppm. {1H}15N-NOE (nuclear Overhauser effect) measurements confirmed that the ETS residues in N117 remained well ordered throughout, similarly as N165, while PEST residues exhibited much lower values as a group (Fig. 3E, inset). Thus, the N117 dimer was a fuzzy complex in which the PEST domain did not deviate from a tethered IDR to the structured ETS domain.

The 2:1 complex formed by PU.1 at a single cognate site suggested that the PU.1 dimer was asymmetric, as a symmetric dimer that exposes the DNA contact surfaces would logically yield a 2:2 complex. However, this stoichiometry was excluded by the DOSY titration data, which showed two inflections with the least diffusive species at a DNA:protein ratio of 1:2, corresponding to the 2:1 complex (Fig. 1B). Unbound PU.1 also formed a homodimer, which could logically arise only if the complex was symmetric. Experimentally, a symmetric dimer was strongly inferred by a single set of 1H-15N signals for unbound N117 at high concentrations (Fig. 3E). Moreover, the CD-detected structure of PU.1 showed negligible changes upon titration by DNA (Fig. 4A), in contrast with the self-titration in the absence of DNA (Fig. 3D). These clues suggested that DNA-bound and free PU.1 dimerized into distinct conformers.

(A) Far-UV CD spectra of the DNA-bound N165 upon subtracting the spectrum of the cognate DNA acquired under identical conditions (75 M and 0.15 M Na+). (B) Residues involved in the DKCDK mutant and in the binding-deficient mutant (R230A/R233A). The structure is homology-modeled against the cocrystal 1PUE. (C) Purification of the DKCDK mutant by ion exchange chromatography under nonreducing conditions. Lysate was loaded at 0.5 M NaCl and extensively washed before elution over a linear gradient to 2 M NaCl. SDS-PAGE of purified fractions is shown. Fractions containing primarily monomer (e.g., 1 and 2) or dimers (e.g., 5 onwards) were concentrated and dialyzed separately into buffer containing 0.15 M NaCl with or without 5 mM DTT, respectively. (D) CD spectra of the DKCDK monomer (top) and dimer (bottom) under various conditions with wild-type N165 as reference. The spectrum for the DKCDK monomer was less well resolved due to the presence of DTT, which contributed to the total absorption of the sample at 50 M protein. See text for details. (E) Fluorescence anisotropy measurements of cognate DNA binding by monomeric and dimeric DKCDK with wild-type N165 as reference. (F) CD spectrum of 25 to 100 M of the R230A/R233A mutant, with N165 at 25 M as reference. (G) DNA loading by the R230A/R233A mutant in the presence of wild-type N165 (solid symbols). Concentrations of the mutant and wild-type protein that individually failed to bind DNA collaborated to bind DNA as a heterocomplex. (H) Proposed model for the formation of two nonequivalent PU.1 dimers: an asymmetric one in the 2:1 DNA complex and a symmetric one without DNA.

To test these notions, we constructed a constitutive ETS dimer via insertion of a single Cys residue into N165, which did not harbor this amino acid, between residues 194 and 195 (Fig. 4B). We targeted this position given its turn conformation in the known structures of the ETS monomer [Protein Data Bank (PDB): 5W3G] and the 1:1 complex (1PUE), and its reported involvement in 2:1 complex formation by heteronuclear NMR (20). Purification of this mutant, termed DKCDK, by ion exchange chromatography under nonreducing conditions eluted monomer and its cystine-linked dimer at >1 M NaCl (Fig. 4C). Fractions containing predominantly monomer or dimer were separately dialyzed into a buffer containing 0.15 M NaCl with or without 5 mM dithiothreitol (DTT), respectively. In the absence of DNA, the far-CD spectrum of the DKCDK monomer (maintained with 5 mM DTT) overlapped closely with the spectrum of N165 (Fig. 4D) and formed the 1:1 complex with cognate DNA similarly as wild-type N165, indicating that the Cys insertion was nonperturbative in the DKCDK monomer (Fig. 4E). In stark contrast, the cystine-linked DKCDK dimer exhibited a CD spectrum that was altogether unlike PU.1 at equivalent molar concentrations (400 M). It bore some similarity to a spectrum for N165 at the highest concentration available (800 M), which contained a greater fraction of dimeric PU.1 (dashed spectrum in Fig. 4D). However, the dimeric DKCDK spectrum was further redshifted by ~7 nm and ~15% more intense. Moreover, the DKCDK dimer bound cognate DNA >100-fold more poorly than wild-type N165 (Fig. 4E). Thus, the DKCDK mutant showed that a symmetric configuration was severely perturbed in conformation without DNA and unlike DNA-bound wild-type N165 (compare to Fig. 4A). Together with a deficiency in DNA binding, the DKCDK mutant demonstrated that the wild-type DNA-bound dimer was not a symmetric species in contrast with the unbound PU.1 dimer.

To assess the feasibility of an alternative, asymmetric configuration in forming the 2:1 complex, which would involve the DNA contact surface, we then examined an R230A/R233A mutant in the DNA-recognition helix H3 of PU.1 (Fig. 4B). The double RA mutant retained an indistinguishable CD spectrum as wild-type N165 (Fig. 4F). At a subsaturating concentration of wild-type N165, the addition of the mutant at a concentration that showed no DNA binding on its own nevertheless produced strong DNA loading (Fig. 4G). Such a result would most simply arise if the RA mutant associated with the wild-type 1:1 complex to drive the 2:1 heterocomplex. The data thus pointed to an asymmetric PU.1 dimer in the 2:1 complex, in which the secondary structure content of PU.1 did not change significantly. Both features contrast sharply with the symmetric conformation required by the DNA-free dimer.

A synthesis of the evidence leads us to propose a model for PU.1 dimerization in the presence and absence of DNA (Fig. 4H). In terms of affinity, the 1:1 active complex is strongly favored (>102-fold) over either the 2:1 complex or the unbound dimer. Excess PU.1 drives one or the other dimeric state depending on the presence of DNA. The key cornerstone of this model is the nonequivalence of the two dimeric states. Specifically, the incompatibility of the free dimer with DNA binding means that a preexisting dimer cannot serve as an intermediate for the 2:1 complex. Thermodynamic insulation of the two dimeric species leads to a mutually antagonistic relationship, in which the formation of one species is favored at the expense of the other. N117 illustrates this antagonism, as relative to N165, the N-terminal PEST domain promotes dimerization without DNA and reduces the affinity of 2:1 complex formation (Fig. 1B). Together with enhancing the apparent affinity for 1:1 binding, the result is a widened concentration window for the 1:1 complex for N117.

The ETS domain as embodied by N165 is highly enriched in Lys and Arg residues, with an isoelectric point (pI) of 10.5. Dimerization should, therefore, be highly sensitive to salt concentration. Contrary to the expectation that the dimer would be stabilized at high salt, which would screen electrostatic repulsion, the opposite was observed. CD-detected self-titration of N165 at 50 mM Na+ showed a nearly complete two-state transition (Fig. 5A) but not at 150 mM Na+ (compare to Fig. 3A). The low-salt spectra, extended in wavelength to 190 nm and protein concentration to 800 M because of the reduced Cl level, showed the same transition characteristics as acquired at 150 mM Na+ (fig. S5), indicating that the same transition was inspected at both salt concentrations. Although the transition at 50 mM Na+ corresponded to a dissociation constant of ~200 M, it was still fivefold higher than that for N117 in 150 mM Na+ (Fig. 5B). The data, therefore, reaffirmed the stimulatory role of the disordered PEST domain in dimerization of the ETS domain while revealing an electrostatic basis in the unbound PU.1 dimer.

(A) CD-detected titration of N167 at 50 mM NaCl from 25 to 800 M. (B) Analysis of the titration by singular value decomposition yields a two-state transition with a dissociation constant K2 of 202 72 M. (C) 1H-15N HSQC as a function of salt from 25 to 500 mM NaCl. Residues with the strongest 1H-15N CSPs (Y173, M223, G239, V244, and L248) are boxed. Inset: Salt dependence of the CSPs of these residues. (D) Summary of the residue CSPs with the average %SASA from the unbound NMR monomer, 5W3G. Residues above a 0.5-ppm cutoff are colored in dark blue, and the subset of internal residues (<35% SASA, based on the termini) is marked with yellow circles. Residues implicated in the DNA-bound dimer are marked with green circles. (E) Mapping of the high-CSP residues to 5W3G. Green residues mark known residues involved in the DNA-bound dimer (20). (F) Chemical shiftderived secondary structure prediction via the CSI using 1H and 15N signals. The color scheme follows the HSQC in (C). Regions with significant changes in secondary structure are marked by arrows. (G) Near-UV CD-detected thermal melting of N117 and N165. Two salt concentrations were evaluated for N165 (blue and gray). Inset: Representative near-UV CD spectra. (H) DSC thermograms (solid) for N165 under conditions (salt and concentrations) in which the protein was primarily monomeric or dimeric. The Cp values are given in kJ (mol monomer)1 K1. Dashed curves represent the two-state transition for a monomer (black) and dimer (blue). (I) Trp fluorescence-detected denaturation by urea of N117 and N165 at two monomer concentrations. Curves represent fit to the linear extrapolation model for a two-state dimer. The marked concentrations represent urea concentration at 50% unfolding.

The sensitivity of the ETS dimer to salt allowed us to access the local structural changes in the DNA-free ETS dimer by NMR spectroscopy. 1H-15N HSQC spectra of N165 with 0.5 to 0.025 M NaCl (Fig. 5C) revealed a panel of residues with significant chemical shift perturbations (CSPs). Taking the spectrum acquired in 0.5 M NaCl as the reference for monomeric PU.1, the CSPs exhibited a well-ordered salt dependence (Fig. 5C, inset). The salt-induced CSPs were plotted as a function of residues (Fig. 5D), and a cutoff of 0.05 was applied to identify the residues most affected by electrostatic interactions. These perturbed residues were spatially diffuse, as a formal mapping to the unbound PU.1 structure demonstrated (Fig. 5E) and did not overlap with the known residues involved in 2:1 complex formation (20). We also examined the transverse spin relaxation (T2) properties of the methyl proton peaks in the 1H spectra as a global representation of the tumbling of N165 at different NaCl concentrations (fig. S6). The effective T2* relaxation values for the three characteristic methyl 1H peaks at 0.025 M NaCl were up to ~25% lower than at 0.5 M NaCl and well beyond experimental error. This result indicated that the salt-induced CSPs reflected the formation of a slower tumbling dimer.

To correlate the NMR data with the CD-detected changes, we used the heteronuclear chemical shifts to infer secondary structure via the chemical shift index (CSI) (28). The CSI results corroborated the CD-detected loss of -helical and gain in /coil content and furthermore localized these changes to helix 1 (H1) and the loop between sheet 3 (S3) and sheet 4 (S4) (Fig. 5F). Local H1 unwinding accounted for the CSPs observed near the N terminus of N165, including the particularly strong CSP at Y173, while the loop between S3 and S4 gained -sheet structure.

The N-terminal IDR promotes a structurally perturbative PU.1 dimer in the absence of DNA. To reveal the underlying conformational thermodynamics of the PU.1 dimer, we performed thermal melting experiments over a range of protein concentrations, using the near-UV CD spectrum from 250 to 300 nm as a probe. The thermal transition was analyzed from a singular value decomposition of the full spectra at each concentration and fitted to a two-state model. The apparent melting temperature (Tm) dropped with increasing concentration in step with the propensity for dimer formation (Fig. 5G). N117 suffered a larger drop than N165 over a ~10-fold increase in concentration. A reduction in salt concentration, which drove dimerization, similarly caused a larger drop in Tm for N165 (0.15 versus 0.05 M Na+; Fig. 5G, dashed line).

The presentation of Fig. 5G as Tm1 versus the logarithm of concentration implies that steeper slopes correspond to lower enthalpies (heats) of dissociation/unfolding, which relate to the quality of conformational interactions. To rigorously define the conformational thermodynamics of the PU.1 dimer, we performed differential scanning calorimetry (DSC) experiments on N165 under conditions (salt and protein concentrations) where the quantitatively major population was either monomer or dimer (Fig. 5H, all values on a per-mole monomer basis). The thermograms showed a much greater calorimetric molar enthalpy (area under the curve) for the monomer (300 M at 0.15 M Na+) than dimer (500 M at 0.05 M Na+). In addition to enthalpy, DSC yields heat capacity changes (Cp, difference in the pre- and posttransition baselines) that inform on changes in water-accessible surface area. The N165 monomer exhibited a Cp of 3.1 0.3 kJ/(mol K), in good agreement with the structure-based value of 3.3 kJ/(mol K) from the NMR structure of the PU.1 monomer (29). In contrast, the N165 dimer exhibited a significantly reduced Cp of 0.97 0.27 kJ/(mol K). Assuming identical thermally unfolded states, the differences in heat capacity changes indicated that N165 was less well folded than the monomer.

To probe the effect of the N-terminal IDR on the conformational stability of the PU.1 ETS domain, we performed chemical denaturation experiments with urea, which could be reported by intrinsic tryptophan fluorescence at much lower protein concentrations than DSC. At a strictly monomeric concentration (1 M) at 0.15 M Na+, N117 was only slightly more sensitive to urea, as judged by the urea concentration at 50% unfolding, than N165 (Fig. 5I). At 100 M concentration, at which N117 is mostly dimeric but N165 remains monomeric, N117 became significantly more sensitive to urea, suggesting highly perturbative interactions between the PEST and ETS domains. A conformationally perturbed N117 dimer was also implied by its volumetric properties. The posttransition density slope in Fig. 3A yields a partial specific volume of N117 of 0.85 0.01 ml/g, which is atypically high for structured globular proteins and suggests altered molecular packing and hydration properties. N165 was more stable at 1 M at 0.05 M Na+ than at 0.15 M Na+, an observation consistent with the ~2C higher apparent Tm for 10 M N165 over the same Na+ concentrations (Fig. 5G). The N165 monomer and dimer were therefore opposite in their conformational stabilities with respect to salt, underlining the structure perturbation by salt or the anionic PEST domain.

(A) Schematic of the phosphorylated Ser residues in human PU.1, marked by green pins. The SerAsp substituted positions in D2N117 and D4N117 are shown. (B) D2N117 and D4N117 exhibit enhanced dimeric propensities without DNA relative to N117 (compare to Fig. 3D). (C) D2N117 and D4N117 are progressively impaired in 2:1 DNA complex formation. (D) The anionic crowders ovalbumin and BSA modulate DNA binding by N117 in a similar way as the phosphomimetic substitutions on N117 to an extent that correlates with their sizes and low pIs. Inset: Stoichiometric determination using 1 M DNA (first binding transition in the case of ovalbumin). The spacing of the ordinates is identical to main plots. The surface potentials of the structures were computed using the Adaptive Poisson-Boltzmann Solver (APBS) at 0.15 NaCl.

In summary, spectroscopic and calorimetric measurements showed that the PU.1 ETS dimer was destabilized with respect to unfolding relative to its monomeric constituents. Structural considerations aside, conformational destabilization contributes to the DNA binding deficiency of the apo ETS dimer. A destabilized dimeric state implied favorable concentration-dependent interactions within the unfolded ensemble over the folded state. The ability of the anionic PEST domain to promote formation of the unbound dimer in N117 therefore further suggests a basis in mitigating the electrostatic repulsion among the cationic ETS domains.

In addition to the N-terminal IDR, the structured ETS domain of PU.1 is also tethered at the C terminus to a shorter, 12-residue disordered segment (residues 259 to 270), as apparent in the unbound PU.1 monomer structure (fig. S7A) (29). Far-UV CD spectra at 0.15 M Na+ showed that hPU.1(117-258) and hPU.1(165-258), termed sN117 and sN165, respectively (fig. S7B), lacked the secondary structure changes characteristic of N117 and 165 across comparable concentrations (fig. S7C; compare to Fig. 3D). sN117 was also much less sensitive to urea over the same protein concentration range as N117, and sN165 showed no change relative to N165. In contrast to their dimeric deficiency without DNA, sN117 and sN165 were both intact with respect to dimerization with cognate DNA (fig. S7D). While sN117 formed 1:1 and 2:1 DNA complexes with the same affinities as N117 in 0.15 M NaCl within experimental error, sN165 was a significantly poorer DNA binder than N165 (table S1). In particular, 2:1 complex formation was less negatively cooperative for sN165, with the concentration window (KD2/KD1) for the 1:1 complex only ~65% that for N165 (fig. S7D). Last, unlike N165 at 0.05 M Na+, sN165 showed a negligible propensity to dimerize and exhibited biphasic binding with cognate DNA (fig. S7E; compare to Fig. 2B). The divergent impact of removing the C-terminal IDR on dimerization with and without DNA stood in clear agreement with our concept of nonequivalent dimeric states for PU.1 and the structural distinctiveness of the two states.

Characteristic of many IDRs flanking DBDs, the N-terminal PEST domain in PU.1 is highly enriched in Glu and Asp residues (pI 3.5), in sharp contrast with the positively charged DBD (pI 10.5) to which it is tethered. The foregoing structural and thermodynamic evidence strongly suggests that the acidic IDR interacts with the ETS domain and shifts it toward dimer formation. Functional studies have established a panel of Ser residues in the PEST domain, including residues 130, 131, 140, and 146 (human numbering), which are multiply phosphorylated in cells (30, 31). Phosphoserines at these positions would enhance the anionic charge density by a substantial amount from 11 (3 Asp + 8 Glu) to 17 (~1.5 per phosphoserine). Because these residues are disordered, we made phosphomimetic substitutions of these residues to Asp, generating a di-substituted (140 and 146, termed D2N117) and tetra-substituted mutant (termed D4N117), to probe their general charge-dependent effects (Fig. 6A). Far-UV CD spectra showed that the phosphomimetic substitutions progressively drove the affinity of the DNA-free dimer, and the resultant dimers appeared to harbor greater random coil content than their wild-type counterpart (Fig. 6B; compare to Fig. 3D). In DNA binding experiments, the di-substituted mutant D2N117 behaved approximately as wild-type N117, while the affinity of the 2:1 complex for the tetra-substituted mutant D4N117 was ~15-fold lower than that for wild-type N117 (table S1). Stimulation of the unbound dimer was therefore associated with a marked reduction in the affinity of the 2:1 complex by D4N117 (Fig. 6C). As a result, the selective effect on the 2:1 complex in D4N117 resulted in greater negative cooperativity (i.e., increasing KD2/KD1) in the dimerization of DNA-bound PU.1. In turn, the concentration window for the 1:1 complex widened more than fourfold for D4N117 relative to wild-type N117.

The reinforcing effects of multiple phosphomimetic substitutions in the disordered PEST domain strongly suggest that it influences the behavior of the ordered ETS domain via a generally electrostatic, nonstructurally specific mechanism. To further establish this notion, specifically the absence of dependence on structurally specific interactions, we tested the effect of crowding concentrations (in the range of 102 g/liter) of ovalbumin or bovine serum albumin (BSA) on DNA binding by N165 (Fig. 6D). These two anionic proteins share pIs (pI = 5.2 and 4.7 for albumin and BSA, respectively) that are close to the PEST domain (pI = 3.5) but present well-formed globular structures. If PEST/ETS interactions involved structurally specific interactions between the two domains, the anionic crowders should differ significantly from the PEST domain in their effects on DNA recognition by the ETS domain. DNA binding in the presence of up to 20% (w/v) ovalbumin showed little effect on the 1:1 complex (Fig. 6D, inset) while progressively decreasing the affinity of 2:1 binding. This behavior mirrored closely the phosphomimetic mutants, and similarly, the more pronounced biphasic appearance in the presence of ovalbumin was a result of the increased negative cooperativity and widening concentration window for the 1:1 complex. With BSA, an even more anionic crowder, the effect was correspondingly more pronounced. A concentration of 5% suppressed 2:1 binding at 105 M, an almost 105-fold molar excess of N165 over DNA. Only the 1:1 complex was formed (inset). In contrast, the neutral crowder PEG 8K preserved biphasic DNA binding (fig. S8A), showing that the effects of BSA and ovalbumin were not due to volume exclusion from crowding alone and highlighting the importance of charge. To test our models prediction that BSA would, therefore, promote the PU.1 dimer, we evaluated N165 labeled with 5-fluoroTrp by 19F NMR in the presence of BSA. The three tryptophan residues in N165 underwent distinct CSPs with 5% BSA under conditions that gave monomers in dilute solution (fig. S8B). These changes reflected conformational perturbations consistent with unbound dimer formation. Thus, phosphomimetic substitutions and acidic crowding supported nonmicrostructural electrostatic field interactions on the ETS domain as the basis of the PEST-stimulated dimerization in the absence of DNA.

PU.1 is a markedly inducible transcription factor during hematopoiesis and immune stimulation (22). Open-source repositories such as the Human Protein Atlas show that the expression of PU.1 varies among a panel of resting cell lines by ~25-fold. Independently, single-cell cytometry shows that the abundance of PU.1 transcript in unstimulated murine bone marrow cells ranges from less to 5% to ~50% that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (32), a housekeeping glycolytic enzyme that is present at ~70 M in the cell (33). Induction by ligands such as retinoic acid (34) or bacterial endotoxins (35) increases PU.1 expression another 10-fold or more. Depending on the combination of cell line, physiology, and the presence of stimulatory ligands, cellular PU.1 abundance varies by a multiplier comparable to the ratio of the two dissociation constants KD2/KD1 (102- to 103-fold) of the 1:1 and 2:1 PU.1/DNA complexes.

In patients and animal models, PU.1 dosage is well established as critical to hematopoietic physiology and dysfunction in vivo (15, 36). Dosage effects have been extensively defined in terms of expression, but relatively little is understood about direct dosage effects on transactivation at the protein/DNA level. In this study, manipulation of enhancer syntax in HEK293 cells, which do not use PU.1, demonstrated negative feedback in ectopic PU.1 trans-regulation, independent of modifying interactions with tissue-specific coactivators. The recapitulation of negative feedback, manifested by dose-dependent derepression of endogenous PU.1 in myeloid THP-1 cells, strongly supports functional relevance in native PU.1-dependent gene regulation. Characterization of the attributable species, a 2:1 DNA complex, revealed two nonequivalent dimeric states that are reciprocally controlled by DNA and the IDRs tethered to the structured DBD. Under physiologic salt conditions, structural alterations that bias unbound PU.1 toward dimerization (e.g., full phosphomimetic substitutions of the N-terminal IDR) oppose dimerization of DNA-bound PU.1. Conversely, alterations that abrogate PU.1 dimerization (e.g., truncation of the C-terminal IDR) promote the formation of the 2:1 DNA complex. Only at low salt conditions (e.g., 50 mM Na+) are the DNA-free and DNA-bound dimers both favored, and the 1:1 complex is not populated. The tethered IDRs do not appear to become part of the structured dimer but determine preference between the two dimeric states such that the DNA-free dimer remains essentially cryptic without both terminal IDRs.

If the 2:1 complex represents the structural basis of negative feedback, what functional role does the unbound PU.1 dimer play? The thermodynamic relationships among the various states accessible to PU.1 (Fig. 4H), critically the nonequivalent free and DNA-bound dimer, suggest a novel push-pull mechanism of PU.1 autoregulation by distinct pools of dimeric protein. By antagonizing the 2:1 complex, we postulate that the unbound dimer suppresses negative feedback and dynamically increases the circulating dose of transcriptionally active PU.1. This model affords for the first time a unifying basis for the PU.1-activating effects of PEST phosphorylation by casein kinase II and protein kinase C (31, 37, 38), as well as the PU.1-inactivating effects of phosphorylation inhibition by oncogenic transcription factors (39), by biasing PU.1 conformations toward or away from the unbound dimer.

Earlier in vitro studies reporting on dimers of the ETS domain (20, 21, 25), including our own, did not appreciate their functional significance. The solution NMR structure of the unbound monomer (5W3G) reflects the incomplete context afforded by the ETS domain alone (i.e., N165) at physiologic ionic strength (0.15 M Na+/K+). The dissociation constant for the PU.1 dimer in dilute solution (105 M) should not be misinterpreted as denoting a physiologically irrelevant interaction. The complex formed by PU.1 and its partner GATA-1 is functionally critical in cell lineage specification during myeloid differentiation in vivo (40), but its equilibrium dissociation constant in dilute solution was 104 M as determined by NMR spectroscopy (41). This and other examples show how volume exclusion and other crowding effects favor interactions in vivo relative to dilute solution. Facilitated diffusion along genomic DNA is also expected to promote cognate occupancy beyond the affinity for oligomeric targets from free solution.

As the tethered IDRs remain disordered in fuzzy PU.1 dimers with and without DNA, their formation is therefore unrelated to paradigms such as induced fit, conformational selection, or fly-casting mechanisms that involve order-disorder transitions by the IDRs (42, 43). Instead, the charged intrinsic disorder in PU.1 is involved in through-space electrostatic interactions. In the absence of the N-terminal IDR, dimerization of the highly cationic ETS domain (N165) is favored by low salt. Conformational destabilization of the resultant dimer under these conditions suggests an electrostatic penalty arising from charge-charge repulsion of the DBDs. The stimulatory effect of the negatively charged IDR on the DNA-free dimer, therefore, arises from attenuation of this repulsive penalty of association. A nonstructurally specific basis is borne out by the similarly favorable effects of reinforcing negative charges via phosphomimetic substitutions in N117 as anionic crowders on N165. As phosphoserines confer higher charge density (~1.5) than carboxylates, phosphorylation is expected to exert an even greater effect than the phosphomimetic substitutions. Notably, despite its nominal designation as a proteasome-recruiting signal, the PEST domain does not target PU.1 for metabolic turnover, but it is associated with a local role in dimerization and protein-protein partnerships such as with the lymphoid-specific factor IRF4 (44).

The properties of the flanking IDRs on DNA binding as revealed in this study highlight the divergent roles played by intrinsic disorder within the ETS transcription factor family, which is united by eponymous, their structurally homologous DBDs. Many ETS members are controlled by autoinhibition, a mechanism that specifically involves short flanking helices in the unbound state that unfolds and disrupts DNA binding allosterically or at the DNA contact interface (45). High-affinity binding to native promoters requires coactivators or homodimerization at tandem sites to displace autoinhibitory helices, forming with positive cooperativity 2:2 complexes (46). The regulatory strategy is activation through recruitment by other coactivators. In Ets-1, the paradigm autoinhibited ETS member, disordered elements in the serine-rich region (SRR) domain upstream of the autoinhibitory helices further modulate the regulatory potency of the autoinhibitory helices. Progressive phosphorylation of the SRR domain reinforces autoinhibition (47). PU.1, and likely its proximal ETS relatives, upends this paradigm. Lacking autoinhibitory domains, high-affinity DNA binding is the default behavior. The disordered elements flanking its structured ETS domain regulate DNA binding by modifying negative feedback. PU.1 is the recruiter in protein-protein partnerships such as IRF4 (44). Phosphorylation of the disordered PEST domain promotes the persistence of the active 1:1 complex and has been established as broadly stimulatory (30, 31, 37, 39). These contrasting features help frame in molecular and functional terms the evolutionary divergence in the ETS family, one of the most ancient families of transcription regulators in metazoan evolution.

As a final remark, both dimeric forms of PU.1 represent highly novel structures. Asymmetric DNA-bound dimers are known in the case of the zinc finger protein HAP1 (48). Zinc fingers are obligate dimers with a 2:2 subunit-to-DNA subsite configuration. Asymmetry in the HAP1 dimer is directed by the polarity of the DNA subsites bound to the subunits. The asymmetric 2:1 complex with PU.1 involves only a single DNA site without significant change in conformation. Functional deficiency of the 2:1 complex as evidenced by the cellular experiments in Fig. 1, therefore, suggests perturbation of DNA structure relative to the singly bound state or denial of specific surfaces of the 1:1 complex to form the transcriptional machinery. In contrast with the localized surface implicated in the 2:1 complex, NMR evidence shows that the residues involved are diffusely distributed with many buried in the PU.1 monomer, leading to a conformationally destabilized dimer. The CSPs observed in the DNA-free dimer, namely, H1 and the wing (S3/S4), were also recently observed for the interaction of PU.1 with a disordered peptide from the SRR domain of Ets-1 (29). These regions may, therefore, represent interaction hotspots for protein/protein partnerships for PU.1 in the absence of DNA. Beyond the minimal ETS domain, the short C-terminal IDR acts in concert with the PEST domain to reinforce the dimerizing properties of the ETS domain. Structurally, this suggests that the two IDRs likely interact physically, either antagonistically in the monomeric state or cooperatively in the dimeric state. In the cytoplasm, the ETS domain mediates nuclear import of PU.1 (49), so dimerization may also help regulate subcellular trafficking. Further studies to solve the structures of dimeric PU.1 and map their distributions in subcellular compartments will define their dynamics in vivo and contributions to target gene expression.

DNA encoding fragments of human PU.1 encompassing the ETS domain with and without various segments of its N- and C-terminal IDRs were synthesized by Integrated DNA Technologies (IDT) (Midland, IA) and subcloned into the Nco I/Hind III sites of pET28b (Novagen). For truncated constructs harboring the PEST domain (i.e., N117, sN117, D2N117, and D4N117), Cys118 was mutated to Ser to facilitate purification and biophysical experiments. Full-length PU.1 used in cell-based experiments was fully wild type. Various PU.1-sensitive enhancer sequences as described in the text were also purchased from IDT and inserted between the Age I/Bgl II sites of pD2EGFP (Clontech, CA). All constructs were verified by Sanger sequencing.

THP-1 and HEK293 cells were purchased from the American Type Culture Collection and were routinely cultured in RPMI 1640 and Dulbeccos modified Eagles medium, respectively, supplemented with 10% heat-inactivated fetal bovine serum. Where indicated, cells were induced with a single dose of PMA at 16 nM for 72 hours (final dimethyl sulfoxide concentration: 0.1%, v/v). All cell lines were maintained at 37C under 5% CO2.

Cellular PU.1 transactivation was measured using a PU.1-dependent EGFP reporter construct under the control of a minimal enhancer harboring only cognate binding sites for PU.1. In PU.1-negative HEK293 cells, the reporter was transactivated in the presence of an expression plasmid encoding wild-type full-length PU.1 and a cotranslating iRFP marker (18). Cells (7 104) were seeded in 24-well plates and cotransfected with a cocktail consisting of the EGFP reporter plasmid (250 ng) and up to 25 ng of expression plasmids for full-length PU.1, using jetPRIME reagent (Polyplus, Illkirch, France) according to the manufacturers instructions. The total amount of plasmid was made up to 500 ng with empty pcDNA3.1(+) vector. Twenty-four hours after transfection, cells were trypsinized and analyzed by flow cytometry using an FCS Fortessa instrument (BD Biosciences). Live cells were gated for iRFP and EGFP fluorescence using reporter and full-length PU.1 only controls, respectively, in FlowJo (BD Biosciences) before computing the total fluorescence of the dually fluorescent population.

Following extraction of total RNA using a spin column kit (Omega) and RT (Thermo Fisher Scientific), RT-PCR reactions were performed on a QuantStudio 3 instrument (Applied Biosystems) with SYBR Green PCR Master Mix (Thermo Fisher Scientific). Expression levels of genes were normalized to gapdh. The primer sequences used for pu.1, csf1ra, e2f1, and gapdh are given in table S2.

Heterologous overexpression in BL21(DE3)pLysS Escherichia coli was performed as previously described (20). In brief, expression cultures in LB or M9 media (the latter containing 15NH4HCl or U-13C6-glucose as required) were induced at an optical density (OD600) of 0.6 with 0.5 mM isopropyl -d-1-thiogalactopyranoside for 4 hours at 25C. Uniformly 15N- and 15N/13C-labeled constructs were expressed in appropriate M9-based media. Harvested cells were lysed in 10 mM NaH2PO4/Na2HPO4 (pH 7.4) containing 0.5 M NaCl by sonication. After centrifugation, cleared lysate was loaded directly onto a HiTrap Sepharose SP column (GE) in 10 mM NaH2PO4/Na2HPO4 (pH 7.4) containing 0.5 M NaCl. After extensive washing in this buffer, the protein was eluted in a gradient at ~1 M NaCl in phosphate buffer. Purified protein was dialyzed extensively into various buffers, as described in the text, and diluted as needed with dialysate. Protein concentrations were determined by UV absorption at 280 nm.

DNA binding by protein was measured by steady-state fluorescence polarization of a Cy3-labeled DNA probe encoding the optimal PU.1 binding sequence 5-AGCGGAAGTG-3. In brief, 0.5 nM of DNA probe was titrated with protein in a 10 mM tris-HCl buffer (pH 7.4) containing 0.1% (w/v) BSA and NaCl at concentrations as stated in the text. Steady-state anisotropies r were measured at 595 nm in 384-well black plates (Corning) in a Molecular Dynamics Paradigm plate reader with 530-nm excitation. The signal represented the fractional bound DNA probe (Fb), scaled by the limiting anisotropies of the ith bound ri and unbound states r0, as followsr=Fb(i=1nrir0)+r0=Fbi=1nri+r0(1)where Fb as a function of total protein concentration was fitted to various models as follows. In all cases, the independent variable was the total titrant concentration as taken.

For DNA binding, the two stepwise dissociation constants describing the formation of the 1:1 and 2:1 PU.1/DNA complexes areKD1=[P][D][PD]KD2=[PD][P][P2D]=KD1(2)where P and D denote PU.1 and DNA. In this analysis, the binding affinities were not further constrained by interactions of the unbound states. The ratio of KD2/KD1 = defines the nature of the cooperativity of the 2:1 complex in the paradigm of McGhee and von Hippel. Values of below, equal to, or above unity denote positively cooperative, noncooperative, and negatively cooperative formation of the 2:1 complex with respect to the 1:1 complex, respectively.

In direct titrations of the DNA probe by PU.1, the observed anisotropy change represented the summed contributions of the two complexes as expressed by Eq. 1. The most efficient approach is to determine binding in terms of the unbound protein, P. The solution, which is cubic in [P], is0=0+1[P]+2[P]2+3[P]3{0=KD1KD2[P]t1=KD1KD2KD2[P]t+KD2[D]t2=KD2[P]t+2[D]t3=1(3)where the subscript t represents the total concentration of the referred species. [P] was solved numerically from Eq. 3, rather than analytically via the cubic formula, to avoid failure due to loss of significance. With [P] in hand, [D], [PD], and [P2D] were computed from Eq. 2 and the corresponding equations of state. In the limit of no formation of the 2:1 complex (i.e., KD2 ), Eq. 3 simplifies to a quadratic, corresponding to formation of only the 1:1 complex0=KD1[P]t+(KD1[P]t+[D]t)[P]+[D]2(4)

Analyses were performed on a Waters Q-TOF (quadrupole orthogonal accelerationtime-of-flight) micro mass spectrometer equipped with an ESI source in positive ion mode. Samples were dialyzed extensively against 0.01 M NH4HCO3 (pH 8) and introduced into the ion source by direct infusion at a flow rate of 5 l/min. The instrument operation parameters were optimized as follows: capillary voltage of 2800 V, sample cone voltage of 25 V, extraction cone voltage of 2.0 V, desolvation temperature of 90C, source temperature of 120C, and collision energy of 3.0 V. Nitrogen was used as nebulizing and drying gas on a pressure of 50 and 600 psi, respectively. MassLynx 4.1 software was used for data acquisition and deconvolution. A multiply charged spectra were acquired through a full scan analysis at mass range from 300 to 3000 Da and then deconvoluted by a maximum entropy procedure (27) to the zero-charge spectra presented. Samples were diluted with dialysate to different concentrations for acquisition and data processing under the same conditions.

Spectra were acquired in 10 mM NaH2PO4/Na2HPO4 (pH 7.4) plus NaCl as a function of concentration or temperature as indicated in the text in a Jasco J-810 instrument. Thermal denaturation experiments were performed at 45C/hour with a response time of 32 s. The path length for near-UV scans was typically 1 or 0.1 mm for far-UV scans. Spectral analysis following blank subtraction and normalization with respect to path length and concentration was performed by singular value decomposition as follows.

For each experiment, a matrix A with column vectors represented by CD intensities at each protein concentration was factorized into the standard decompositionA=UVT(5)where the left-singular unitary matrix U contained the orthonormal basis spectra ui scaled by the singular values i from the diagonal matrix . The row vectors in the right singular unitary matrix VT gave the concentration- or temperature-dependent contribution of each basis spectrum to the observed data and is termed as transition vectors vT in the text. For ease and clarity of presentation, the scaling due to is captured into the transition vector, i.e., a = u(vT) (matrix multiplication is associative), which has no effect on the fitted parameters. The transition vectors were fitted to titration models describing a two-state transition with dissociation constant K as followsX=F1n(XnX1)+X1=F1nX+X1(6)where X = vT and the subscripts 1 and n refer to monomer and oligomer (n = 2 for dimerization), respectively. F1n is given byKn=nptn1(1F1n)nF1n(7)where F1n is the fractional two-state 1-to-n oligomer at equilibrium and pt is the total protein concentration. As detailed elsewhere (26), a fundamental feature of Eq. 7 is that dimerization is uniquely nonsigmoidal on linear scales, which is diagnostic for two-state dimers. Any higher-order oligomer processes are invariably sigmoidal on linear scales.

NMR experiments were conducted at 25C using Bruker BioSpin 500, 600, or 800 MHz spectrometers. For DOSY experiments, unlabeled protein and DNA were co-dialyzed in separate compartments against the required buffer, lyophilized, and reconstituted to 250 M in 100% D2O before data acquisition at 500 MHz with a 5-mm total body irradiation probe. For two-dimensional (2D)/3D experiments, uniformly labeled N165 and N117 ( unlabeled DNA) were dialyzed against the required buffer at 11/10 excess concentration and adjusted 10% D2O at 400 to 700 M protein. The dependence of the DOSY-derived self-diffusion coefficients on total protein concentration was fitted using Eq. 6, with X corresponding to the diffusion coefficients of the oligomer and monomer.

1H-15N correlated measurements were made using a phase-sensitive, double inept transfer with a garp decoupling sequence and solvent suppression (hsqcf3gpph19). Spectra were acquired with 1k 144 data points and zero-filled to 4k 4k. Steady-state heteronuclear {1H}15N-NOE was acquired at 600 MHz from the difference between spectra acquired with and without 1H saturation and a total recycle delay of 3 s. The data were processed with TopSpin 3.2 to extract peak intensities and fitted as single exponential decays.

Spectra were assigned with purified 13C/15N-labeled constructs in a standard suite of 3D experiments: HNCA, HNCACB, HN(CO)CACB, HNCO, and HN(CA)CO at 800 MHz using a 5-mm TCI cryoprobe for bound protein to DNA and at 600 MHz using a 5-mm QXI resonance probe for unbound protein. Spectra were processed using NMNRFx software, referenced to 4,4-dimethyl-4-silapentane-1-sulfonate (DSS), and peak picked/analyzed with NMRFAM-Sparky. Automated Assignments were made using the NMRFAM Pine server and verified manually.

The intrinsic fluorescence from three tryptophan residues in the PU.1 ETS domain was excited at 280 nm and detected at 340 nm with a slit of 15 nm for excitation and 20 nm for emission. Intensity data recorded in the vertical and horizontal polarizer positions were corrected for the grating factor and by blank subtraction. Concentration-dependent anisotropies were fitted to Eqs. 6 and 7, where X = r. For denaturation studies, PU.1 at 100 M and 1 M in 10 mM tris-HCl buffer (pH 7.4) containing either 0.15 or 0.05 M NaCl was titrated with urea. Blank-subtracted intensity data were directly fitted with the linear extrapolation method.

Protein samples were exhaustively dialyzed against 10 mM NaH2PO4/Na2HPO4 (pH 7.4) and 0.05 M NaCl over 48 hours with at least three buffer changes. The final dialysate was reserved and used to rinse and fill the reference cell as well as diluent for the samples. Thermal scans were carried out at 45C/hour from 10 to 80C using a MicroCal VP-DSC instrument (Malvern). All scans were carried out only when the baseline was reproducibly flat. Thermograms were fitted to two-state transition models. Nonpolar and polar solvent-accessible surface area (SASA) for monomeric N165 was estimated from the solution NMR structure 5W3G (29) based on a 1.4- probe. SASA for the unfolded state ensemble was provided by the ProtSA algorithm. The change in SASA in angstrom was converted to heat capacity change in kilojoule mol1 Kelvin1 using coefficients as followsCp0=(0.320.04)Anonpolar(0.140.04)Apolar(8)

Solution densities were measured in 10 mM tris-HCl (pH 7.4) at 25C, containing 150 mM NaCl using an Anton Paar model DMA-5000 vibrating tube densimeter with a precision of 1.5 106 g/ml. The partial molar volume of the solute V was determined from the following relationship=0+(MV0)c(9)where 0 is the density of the buffer, c is the molar solute concentration, and M is the molecular weight of the solute. For a two-state dimeric species, the observed density was analyzed as followsobs=F1n2+(1F1n)1(10)where F1n is as defined by Eq. 7, with n = 2. Because the observed density varies with the concentration of any species, 1 and 2 are each treated as linear functions as described by Eq. 9.

Acknowledgments: We thank D. Beckett and W. D. Wilson for insightful discussions and L. McIntosh for providing a structure of the unbound PU.1 ETS monomer (5W3G) before publication. We also acknowledge with appreciation the many excellent suggestions from the reviewers. NMR data presented here were collected, in part, at the City University of New York Advanced Science Research Center (CUNY ASRC) Biomolecular NMR Facility. Funding: This investigation was supported by NSF grant MCB 15451600 and NIH grant R21 HL129063 to G.M.K.P. S.X., H.M.K., and S.E. were partially supported by GSU Molecular Basis of Diseases Fellowships. V.T.L.H. was supported by the GSU University Assistantship Program. Author contributions: S.L. and H.M.K. carried out cell-based studies. G.M.K.P. cloned the molecular constructs. S.X. and S.E. expressed and purified the recombinant protein constructs. S.X., S.E., J.M.A., and M.W.G. performed and analyzed the NMR experiments. S.W. performed and analyzed the data from the ESI-MS studies. V.L.T.H. performed the densimetric experiments and analyzed the volumetric data. S.X., M.K., G.L.F., and A.V.A. performed the binding, thermodynamic, and other spectroscopic experiments. S.X., M.W.G., and G.M.K.P. jointly designed the studies, analyzed data, composed the figures, and wrote the paper. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Here is the original post:
Intrinsic disorder controls two functionally distinct dimers of the master transcription factor PU.1 - Science Advances

Stem Cell Therapy Market: Business Opportunities, Current Trends and Industry Analysis by 2018 2028 – Instant Tech News

Stem Cell Therapy Market Insights 2019, is a professional and in-depth study on the current state of the global Stem Cell Therapy industry with a focus on the Global market. The report provides key statistics on the market status of the Stem Cell Therapy manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2019-2025 global Stem Cell Therapy market covering all important parameters.

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

The key points of the Stem Cell Therapy Market report:

The report provides a basic overview of the Stem Cell Therapy industry including its definition, applications and manufacturing technology.

The report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2019-2025 market shares for each company.

Through the statistical analysis, the report depicts the global total market of Stem Cell Therapy industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

The report then estimates 2019-2025 market development trends of Stem Cell Therapy industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

The report makes some important proposals for a new project of Stem Cell Therapy Industry before evaluating its feasibility.

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

There are 3 key segments covered in this report: competitor segment, product type segment, end use/application segment.

For competitor segment, the report includes global key players of Stem Cell Therapy are included:

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Reasons to Purchase this Report:

* Estimates 2019-2025 Stem Cell Therapy market development trends with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects

* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Read more from the original source:
Stem Cell Therapy Market: Business Opportunities, Current Trends and Industry Analysis by 2018 2028 - Instant Tech News

Anatomy of a grant: Ashley Kramer’s yearlong journey to finding her doctoral thesis – The South End

He asked her for a list of dream projects she would love to investigate. What followed was a year of challenges, stresses and the ultimate reward guided intellectual freedom toward scientific discovery.

Ashley Kramer, a student at the Wayne State University School of Medicine, is enrolled in the schools M.D.-Ph.D. program, an eight-year commitment broken down into three parts the first two years of medical school, four years of graduate school, then the final two years of medical school. Like all M.D./Ph.D. students at the medical school, Kramer had to complete research rotations with faculty she thought would make good dissertation advisors.

Because I have always loved stem cell biology and had experience working with zebrafish in the past, I decided to do an eight-week rotation in Dr. Thummels lab between my medical year one and medical year two, and made the decision that this was absolutely the perfect lab for me, she said.

Ryan Thummel, Ph.D., is an associate professor of Ophthalmology, Visual and Anatomical Sciences. His lab focuses on retinal development and regeneration in zebrafish, an attractive model to study neurodegenerative diseases because of its ability to regenerate neuronal tissues. Zebrafish fully regenerate their retinas in just a matter of weeks, an ability mammals lack.

Zebrafish and mammals both have a cell called Mller glia that supports retinal neurons. In zebrafish, however, these cells convert to stem cells and are responsible for retinal regeneration.

At the end of the rotation, Dr. Thummel floated the crazy idea of starting to work on this grant, a 70-plus page monster undertaking, during my M2 year, and I immediately jumped at the opportunity. I was excited at the idea of having a four-year research project completely planned out by the time I started my Ph.D. after M2 so I could hit the ground running after the dreaded STEP 1, Kramer said.

I came to him two days later with a nine-page document of project ideas. We sat down for three hours discussing projects and came up with a top-two list of cohesive projects for me to move forward with as a grant and thesis, she said. From there, it was a nearly yearlong process of writing, meeting, revising and repeating for each of the many sections of the grant.

The effort was worth it. Kramer secured a five-year, $294,102 grant from the National Eye Institute of the National Institutes of Health last year to study the molecular mechanisms of retinal regeneration in zebrafish, an organism that exhibits a remarkable capacity for regeneration.

"Ashley is a dedicated young scientist and worked very hard on this grant application," Dr. Thummel said.

The grant is one of the NIHs Ruth L. Kirschstein National Research Service awards, also known as an F30. The project, Elucidating the role of DNA methyltransferases in epigenetic regulation of retinal regeneration in the zebrafish, started last month. She is the principal investigator.

This was an incredibly challenging experience that allowed me to grow immensely as a scientist. Grant writing, planning effective and novel longitudinal scientific investigations, and time management will all be critical skills for me moving forward in my career as a physician scientist, she said. I cannot thank Dr. Thummel and my past advisors enough for all of their mentoring and support in the last ten years who have gotten me to where I am today, and I am looking forward to the rest of my training here at Wayne State and beyond.

Kramer earned her bachelors degree in Genetics, Cell Biology and Development from the University of Minnesota in 2014. Her love of research and stem cell biology started when she was an undergraduate research assistant there.

Nearly a decade later, she is studying how epigenetic marks are added to, and removed from, genes in zebrafish retinal stem cells during the process of retinal regeneration. The role of epigenetics in the body is akin to traffic signs on the road.

If roads had no traffic lights, stop signs or barricades, it would be complete chaos. The same is true for your cells. If you used every single gene encoded in your DNA 100% of the time, your cells would be chaos. Epigenetics is what is responsible for telling your skin cell to be a skin cell and your liver cell to be a liver cell, while they both have the exact same underlying DNA sequence, Kramer said. There are various different epigenetic marks that decorate the DNA without actually changing the sequence. These marks come in many forms and can act to either start, stop or change the amount that a particular gene is used, similar to how a green light, road block or stop sign direct traffic rules.

The process is critical for normal embryonic development and everyday cell processes.

If we can gain a deeper understanding of how species like the zebrafish are able to regenerate tissues when mammals cannot, despite having the same cell types, we may be able to start working to translate those mechanisms to mammals, she said. It is possible that certain regeneration pathways have been epigenetically silenced through evolution and we may be able to use modern advances in gene therapy techniques to unlock regenerative capacity in mammals.

Follow this link:
Anatomy of a grant: Ashley Kramer's yearlong journey to finding her doctoral thesis - The South End

The Challenge of Bioethics to Decision-Making in the UK – Westminster Abbey

Past Institute lectures

A lecture for the Von Hugel Institute series Ethics in Public Life, 5th February 2015, given by Claire Foster-Gilbert, Director, Westminster Abbey Institute.

The context of the series of lectures of which this is one is ethics in public life, and I would like to start by taking some time to describe the creation and operation of Westminster Abbey Institute, and use it as a prism for our consideration of bioethics and decision making in the UK. I want to say a little bit about the sacred-secular divide which I do not see. Then the two thorny examples I will use in bioethics, when I come to them, will be embryology and assisted dying.

Westminster Abbey Institute was launched in November 2013 to revitalize moral and spiritual values in public life, working with the public service institutions around Parliament Square, and drawing on its Benedictine resources of spirituality and scholarship.

Westminster Abbey sits on the south side of Parliament Square, with the Judiciary in the form of the Supreme Court on the west side, the Executive in the form of Whitehall on the north side, and the Legislature in the form of the Houses of Parliament on the east side. The Institute is the Abbeys answer to the question: what is it bringing to public service and how can it support those in public office?

We knew, when we started, what we were not: a think tank, part of the commentariat, a campaigning organisation, nor a fawning courtier. Nor were we apologists for religion in the public square. The Abbey is already more integrated than that. There is no sense of a sacred-secular divide, and as I go about my work as Director I feel none between my work and that of the public service institutions around the Square. The similarity is that we are identifying at the heart of the Parliament Square endeavour a sincere wish to support the good, to serve society, to make things better in the world. And in that sincere wish I see spirit moving, hearts opening, minds analysing, bodies acting, as a holistic, responsive flow to the call of public service.

I am not naive: the motivation to serve the public and the vocation to public service are not pure. In amongst the good wheat of service are the tares of motives such as selfish ambition, personal gain, fame, and the needy weakness of human nature to be recognised and rewarded. I see those other motives, but I know them for my own also, so am in no position the Abbey Institute is in no position, lets be clear to judge or condemn them. Like the parable, we leave that till the harvest. And meanwhile, by supporting the good, believing in the motives that are for service, recognising and applauding the rightness in the work around the Square, the murky tares, if I may torture the analogy beyond its capability, melt away. We hope.

I see a wholeness, then, responding to a call to serve. The deeper the response the more effective and lasting it will be and here is a place where our religion makes a specific contribution. The further back into God it reaches, the more effective and lasting and good the call to public service will be. I call it God. Spirit, depth, the swirling deep movement of creativity, the meditation of the soul, the rest before action. The further the archer draws back the bow, the further and truer the arrow will fly. It has been notable just how much of a longing for depth has shown itself in the people and institutions around the Square in the short time the Institute has been operating.

Our method is first to offer a Benedictine context. That is, we offer conversation that locates itself in stability, community and the conversion of manners. We will sit down with a group of, say, senior Civil Servants, or those tasked with offering professional development to MPs, or a group of Peers, and together we will devise a seminar for their department or group which will look at the good that the department or group is trying to do. What is significant and distinctive is that the psychological and philosophical location of the conversation is deep. That depth is also physically expressed by the Jerusalem Chamber where King Henry IV died and V became King, and the King James Version of the Bible was finalised, and so forth, where the seminars happen. Part of the Abbots and then the Deans lodging, a space where spiritual and worldly do not separate.

I was set a great example of how to do depth by Rowan Williams when he was the interlocutor for a series of four public conversations at St Pauls Cathedral, taking in turn global economy, ecology, governance and health, and asking the experts in those fields questions which immediately drew them into a consideration of the philosophical and even theological underlying currents of the subjects. The bishops did a similar thing with genetics experts when they spent a day learning about the subject. They were really good questions, and ones that practitioners, officials, public servants often dont have time to ask, but they are the most important questions because they lead us into our spiritual humanity.

A really lovely example emerged yesterday when we were sitting around the table in the Permanent Secretarys office of a Government Department, discussing a forthcoming seminar for the Department. One of the Civil Servants spoke about how too often officials in the Department will apply formulaic approaches, such as the benefit-cost ratio, in a way that masks or even undermines vital human qualities such as empathy and humility, and we will look at this in the seminar. Importantly, the words and the disposition came from the Civil Servant, not from the Abbey Institute. We are not functioning on the Square to tell others what the Good is. It emerges in the encounter.

So the conversation is located in a Benedictine place (in a way, for a short while, that Permanent Secretarys office became a Benedictine space). First, it is stable, it is safe here, and here is not going to go away, its an historical place where we can feel our own passing, gain a perspective on our place in history. Second, it is a place of community, which means that we are gathered in goodwill together, seeking the good together, united in our efforts and made companions in our purpose, not by any means agreeing with each other but feeling safe with each other. As a community of goodwill we feel it is safe to get things wrong, to take time to form conscience, to work things out. And of course we operate to the Chatham House rule. Third, we are about the conversion of manners. We expect transformation to take place though we dont necessarily know what it will be. Broadly, though, borrowing from Philip Shepherd, we will be looking for moves:

And I dont mind admitting that this transformation is probably only realised after the talking is over and everyone has gone to evensong and then wandered around the Abbey in the semidark and silence of the close of the day and had a glass of wine back in the Jerusalem Chamber!

In agreeing that we are a community of goodwill seeking to articulate the good I have offered an analogy from sailing that works well. A Government Department can be imagined as a sailing boat. At the helm stands the Permanent Secretary, who, like all good helmsmen, seeks never to steer the boat more than five degrees either side of the compass direction upon which the boat is set. Civil Servants in the Department form the crew, from the navigator who must know the course and ensure the helmsman anticipates obstacles, to the scrubber of decks who ensures no one slips up. All play their part in ensuring the boat remains shipshape and able to withstand the waves and the winds in travelling its appointed course.

The waves are the events of the nation and the world. They may be relatively calm or they may rise into steep and stormy mountains of water, threatening the stability of the boat.

The winds are public opinion, which can fill the sails of the boat and send it scudding on its chosen course. They can gust and buffet, interrupting the boats smooth journey. Or they can blow adversely, threatening to push the boat off course altogether.

Hence, the helmsman cannot simply hold the tiller fixedly. He or she must constantly respond and adjust to the wind and the waves, aiming to keep within five degrees either side of the compass direction or risk increasingly over-compensatory swings away from the course of travel.

The compass point towards which the boat is sailing is The Good. As such, it is not a destination; the journey is the thing, the direction of travel the concern, not the arrival.

By whom is The Good defined? It is true that the Government Minister is granted that responsibility and privilege by virtue of having been elected by universal franchise. But in defining The Good, Ministers have to have their Partys support. And of course the strength of the prevailing wind, public opinion, may be such as to determine a change of compass direction altogether. For the politician, public opinion will set parameters on what he or she can achieve. The great political leader will have a vision of the Good that transcends narrowminded concerns but retains Party support, and respects the parameters set by the prevailing wind of public opinion. The visionary and skilled politician will learn, quite possibly from his or her Civil Servants, about the art of tacking.

Because of course it is the helmsman and the crew who execute the tack, and any other sailing manoeuvres required. The Civil Service crew, having gathered the evidence sniffed the wind, watched the waves will need to be able to tell Ministers when their proposed direction of travel will not work: when, whatever the Ministers might want to think, their proposed direction is possibly not towards The Good. Thus the Good is sought by all.

And in passing, if one imagines Whitehall as a fleet of boats, those, too, will need to be taken into account by the helmsman. But and it is a wonderful sight sailing boats, journeying as a fleet in the same direction across the waves, subject to the same wind, stay uniform distances apart.

Having established a common concern with identifying the Good, seated in our Benedictine space, we then spend time as moral philosophers, looking at the specifics of the policy drivers for a given Government Department. Our analysis is rigorous, using the method I developed in the Centre of Medical Law and Ethics at Kings College, London, under Ian Kennedy, in the 1990s.

We use the three broad approaches that moral philosophers have taken over the centuries as they have sought to determine what is good. These we have called goal-based, duty-based and right-based, following Dworkinii, Botrosiii and Fosteriv. Very briefly and broadly, a goal-based thinker will see the good of an action in its consequences rather than in the content of the action itself; a duty-based thinker will look at the action and judge it according to preexisting moral rules; and a right-based thinker will judge the action according to the views of those most affected by it. The goal-based approach is valid insofar as it is the case that we rarely act without some end in view and it is right to consider whether that end is a good one. The goal-based approach is limited in that even very desirable goals should not justify actions which in themselves are intrinsically nasty. The ends are important moral considerations but they dont justify the means. Morality is not a mathematical exercise. The duty-based approach is valid in that it makes us think hard about what we are doing rather than merely why we are doing it, recalibrating the needle of our moral compass, making us morally sensitive rather than mathematically certain. The duty-based approach is limited because it can blind us to important consequences (Kant would have us truthfully respond to a murderer seeking her prey); and it is limited because it can make us arrogant: concerned only with our own place in heaven earned by doing the right thing, regardless of its effect or the views of others (the poor soul who will be murdered because Kant refused to tell a lie, or the patient who wants his life support switched off and we refuse to take a life). The right-based approach is valid because it requires us to listen to others, it makes us community-minded instead of purist. It is limited because on its own it would make someones request, for example, to take their life, right with no other consideration except that it is their wish.

All three approaches are needed. They conflict, they make us think, they require sensitive responses, honest appraisal, self-awareness because we will temperamentally favour one approach over the others, but taken together they form a three-legged stool that stands firm, if the legs are all of the same length, even on rocky ground.

And then comes the real challenge of bioethics. The Department of Health wants us all to live better for longer. But when does life begin and when does it end? I want in this third and final part of my lecture to explore the contemporary challenge of these questions by looking at two issues embryology and assisted dying that have been working their way around Parliament Square, with cases in the Supreme Court, policy development in Whitehall, and legislation or attempts at legislation in the Houses of Parliament.

Human fertilisation and embryology are scientifically complex and they are also, at every stage, morally sensitive. The challenge to Government and Parliament has been whether and how to draw these extraordinary scientific developments within a regulatory framework in a way that respects the science and does not ride roughshod over the sensitive moral questions, or ban the research and practice altogether. Having chosen the former course of action, what principles needed to underlie the regulatory framework?

Let us take a step back in time and thought. Let us bring the issue into our safe Benedictine space. Here we are allowed to think out aloud. We do not have to have a pre-determined position, but if we do, we wont be shouted down or assumed to be on the side of the devil.None need feel defensive. In this Benedictine space we are seeking the Good, aware that many have tried before us and God willing there will be many afterwards, all calibrating their moral compass and seeking to steer the boat no more than five degrees either side of the compass point, but having to allow, because of the wind of public opinion and the waves of ever changing events, that much leeway either side. We know we will not find perfect answers.

And now for the three-legged framework. From a goal-based perspective, we ask what embryology is for, and why it matters. Embryology is important as a cure for infertility, as a therapeutic response to currently incurable diseases using cell transplantation and, very recently proposed, eliminating mitochondrial disease altogether. Its goals, then, are for life: new life, and curing diseased life. No one, really, could argue with the goals of embryology. We would want the research and practice to be done excellently, so as to ensure these good goals were reached, but from a goal-based perspective, taken on its own, there can be no quarrel with it.

From a duty-based perspective, what does embryology involve? Here the moral questions start to bite. The first question must be about the status of the embryo itself. Because if the embryo has the same status as a human life, no matter how wonderful the goals are, no one would countenance destroying a human life to reach them, and embryology (which always involves destroying embryos) would fall at this moral fence.

The reasons you might regard the embryo as a human life are as follows: the embryo is formed from the fertilisation of an egg by a sperm forming a unique genome no one (if it is a person) was ever like it before, and no one will be ever again. We, each of us diverse people, were all embryos once. If we are to choose a point when life begins, the formation of the fertilised egg is certainly a definite stage one could choose.

The reasons you might not regard the embryo as human life are: the place of fertilisation is not the womb or the field in which the embryo is implanted, but at the base of the fallopian tubes. The embryo still has a journey to make to reach the womb and implant. (Some Shia teaching on this argues that life cannot be said to have begun until the seed, egg and field are all in place, ie at implantation.) During that journey, in the normal course of events, 70% of embryos do not reach the womb. It is during that journey that the all-important stem cells start to proliferate, hence the interest in the early, pre-implanted embryo, not the fetus in the womb. During that journey, the embryo may divide and become more than one fetus, hence genetically identical twins. These reasons may persuade you that it would be acceptable to see the early embryo not as human life but as potential life, and that its use therapeutically is acceptable. You may feel the goal-based tug: the status of the early embryo is in question, and the use of them therapeutically is so full of promise Should the duty-based consideration, that the embryo has independent moral status like that of a human being, give way?

What is important to recognise is that we do not say that the embryo has no status. The legislation has recognised its moral importance by regulating its use. But the law has accepted that the embryo is not the same as a human life.

From a right-based perspective, you cannot really make a judgement. The embryo cannot speak for itself. Is it fanciful to conduct a thought-and-feeling experiment predicated on the fact that we were all embryos once. Would we be happy to have been destroyed even before reaching the womb, to save another life or lives, or to create a new life? ??

The other right-based question relates to those who might benefit from stem cell or mitochondrial therapy: if they think of the embryo as having human status they may not want to benefit from such treatment. Healthcare practitioners may seek to be conscientious objectors.

The challenge to UK decision-making of embryology has been profound and I think, myself, that we have not done badly at it. Prior to this last development on mitochondrial DNA, the debates have been long and thoughtful, no speedy legislation was drawn up (except to prevent cloning), and the regulation is careful. In the UK, embryo research can take place but it is all regulated. (In the US, embryo research may not take place if it is federally funded; if you can pay for it yourself, you can do what you like!)

However, courts continue to be referred to as no legislation could possibly anticipate the science. It has turned out that the most fruitful source of embryonic stem cells has not come from embryos but from de-differentiated adult cells. Since however these de-differentiated cells, if placed in a womb, could theoretically grow into a clone of the person whose cell it was, this has had to be specifically outlawed and, much more recently, and potentially worryingly, a court has ruled that: The mere fact that a parthenogenetically activated human ovum commences a process of development is not sufficient for it to be regarded as a human embryo. This judgement opens the way to patenting the process of creating stem cells. It is potentially worrying since it arguably robs the embryo of its moral status. However, what is the status of a de-differentiated cell, which could originate from any one of the bodies in this room just by scraping our skin?

Is the very recent decision of the Commons to allow the process that removes diseased mitochondrial DNA from the offspring of mothers with the disease a case of slipping down a slippery slope into unethical waters? Is it the first step towards eugenics, since it eliminates the disease from the germ line permanently? Or is it an intelligent use of skills and techniques we have developed through carefully regulated embryo research, that will allow the cure of a vile disease?

Assisted dying, unlike embryo research, has not been made legal and given a set of regulations by which to abide. Despite its repeated return to Parliament and the apparent public support for a change in the law, none has happened, as yet. In practice, cases have been decided by the Courts and the number of cases coming to the Courts is only increasing. It is something of a sore point for the judges: they cannot turn cases away. All the time, as they see it, Parliament refuses to take the bull by the horn and create legislation, they are obliged to give judgements on a case by case basis that creepingly changes the law, and it is changed by lawyers not by democratically elected representatives of the public debating in public.

Before reflecting on the challenge to law and policy-makers that assisted dying has posed, let us once again step back into our Benedictine space, and we should pause here for a moment and recollect that the primary quality of that space is listening

And now conduct our analysis. Assisted dying is the act of making available to a person, who has expressly and competently asked for it, the means to take his or her life by their own hand.

From a goal-based perspective, one goal of assisted dying is to alleviate suffering. Another is torespect the autonomy of individuals. Another may be put more boldly: to end life deliberately.

From a duty-based perspective, principles of the sanctity of life and of respecting autonomy both raise their concerns, and conflict. How are they resolved?

From a right-based perspective, the principle of respect for autonomy trumps any duty of other individuals to save, sustain or end life. It is, simply, up to the individual. When polls are taken on the subject of assisted dying and euthanasia the vast majority of responses are in favour of it, on the grounds, though, that it is my life to do with as I please and who is any doctor to prevent me. But a law that permitted a solely right-based approach that the request should be granted simply because it had been made would be impossible to apply. It would be impossible to know if the person had actually asked for death, because they would be dead. Additional safeguards have to be included in any legislation, and these require that certain relevant professionals are satisfied that the conditions allowing assisted dying are met. This is not, then, a purely rights-based activity any more. Similar difficulties arise in seeking abortion - it is not, in the legislations, simply up to the mother whether or not the abortion takes place. She has to satisfy two doctors that she fulfils the criteria set by the law. The fact that doctors will very often sign the forms without questioning the mother, because they take a right-based approach in profoundly believing in her right to choose, is symptomatic of the challenge of lawmaking in areas of bioethics.

If the dying in question is assisted only, ie the person has to take the lethal substance themselves, this right-based problem is allayed. That is to say, we may be fairly sure that if the pink drink given by organisations such as Dignitas is drunk without assistance once it is put in the hands of the one seeking assisted dying, then he or she most definitely did want to die.

We cannot know what passes in their hearts however, and Mary Warnock has been worryingly at ease with the idea that it would be perfectly all right to seek euthanasia on the grounds that one felt a burden to ones family and friends. The wishes and needs of the community of that individual: family, loved ones, society are all included in the right-based approach, and what of these? Chaplains ministering to those receiving euthanasia in Holland speak of the devastation of families, resonant of the desolation of the families of suicides.

The most recent case that came to the Supreme Court was that of Nicklinson, Lamb and the Director of Public Prosecutionv. Nicklinson and Lamb were both almost entirely paralysed; Nicklinson from a stroke which left him able to blink only and Lamb from an accident that meant he could only move his right hand. Hence neither would be able to take the pink drink unaided, so both wished to be assisted to die without fear of prosecution of those who helped. The Director of Public Prosecution sought the freedom to decide on the matter of assisting suicide on a case by case basis.

In the Supreme Court, all the Law Lords agreed that Article 8 of the Human Rights Act (which is the right to a private life, to be overridden only in the case of threats to public safety or criminal acts) is relevant to the issue of assisting someone to die if it is their express wish. That is to say, domestic rulings can be made by way of interpretation of the Article in relation to assisted suicide. But while some Law Lords believed that it was a right for a person to be assisted to die if it was their express wish, according to Article 8, others did not. It was recognised that there was a fundamental incompatibility between the sanctity of life and autonomy. Several Law Lords argued strongly that the debate should be held in Parliament as the representative body of society, not judged upon by appointed Justices. And indeed there is yet another bill to allow assisted dying making its way through the House of Lords now. It has reached the stage where the Lords are working through more than 100 amendments, some of which are clearly intended to wreck the bill, whilst others provide clarification and strengthening of safeguards. And arguably the intellectual purity of the moral reasoning of the judges is a better place to turn to than the mess of Parliamentary debate. What a strange way for law on such a sensitive and controversial issue as the management of the dying process to be written: by the tug of war of differing factions and the compromise that will inevitably be reached if the bill is to succeed.

And yet, how are we to decide these matters that affect us all? I should like to finish, provocatively, with a lengthy quotation from a recent lecture delivered by one of the Justices of the Supreme Court, Lord Sumption.

To sum up, then. We have considered challenging and complex bioethical issues using the Westminster Abbey Institute approach of first, creating a Benedictine space of safety and stability, second, subjecting the matter to rigorous moral analysis and third, coming to a decision, which decisionmaking is the responsibility of the lawmakers and the policymakers. What I have not done is to offer absolute rules or principles which trump every other consideration. It is far better to be morally sensitive than to be morally certain. And so I am agreeing with Lord Sumption that, however fallible it may be, Parliament is the place to fashion legislation on these matters. We do well to attend to whom we put there.

(i) Philip Shepherd, New Self, New World: recovering our senses in the twenty-first century, (Berkeley: North Atlantic Books), 2010 (p 282)(ii) Ronald Dworkin, Taking Rights Seriously, 1977 (Harvard: Harvard University Press)(iii) Sophie Botros and Claire Foster, The moral responsibilities of research ethics committees, in Dispatches, 3:3, Summer 1993(iv) Claire Foster, The Ethics of Medical Research on Humans, (Cambridge: Cambridge University Press) 2001(v)R (on the application of Nicklinson and another) (Appellants) v Ministry of Justice (Respondent); R (on the application of AM) (AP) (Respondent) v The Director of Public Prosecutions (Appellant); R (on the application of AM) (AP) (Respondent) v The Director of Public Prosecutions (Appellant) 25 June 2014(vi) Lord Sumption, The Limits of Law, 27th Sultan Azlan Shah Lecture, Kuala Lumpur, 20 November 2013

Download a transcript of this lecture (PDF, 238KB)

Continue reading here:
The Challenge of Bioethics to Decision-Making in the UK - Westminster Abbey

The 411 on Stem Cells: What They Are and Why It’s Important to Be Educated – Legal Examiner

Medical treatment involving stem cells is an ever-growing, billion-dollar industry, so chances are you have heard about it in the news. Here in the U.S. and around the world, stem cells are being used in various therapies to treat a wide variety of health problems and diseases, including dementia, autism, multiple sclerosis, cerebral palsy, osteoarthritis, cancer, heart disease, Parkinsons disease, and spinal cord injury. Treatments for such health issues may sound promising, but the risk is many of those being sold and advertised arent yet proven to be safe and effective. This is why its so important to educate yourself before jumping into any kind of stem cell treatment.

What are stem cells?

To gain a better understanding of this new age of medical research, one must first understand what stem cells are and how they work. Stem cells are special human cells that can develop into many different types of cells. They can divide and produce more of the same type of stem cells, or they can turn into different functioning cells. There are no other types of cells in the body that have this natural ability to generate new cell types.

Where do stem cells come from?

So where do stem cells that are used for research and medical treatments come from? The three main types of stem cells are embryonic (or pluripotent) stem cells, adult stem cells, and induced pluripotent stem cells.

Embryonic stem cells come from unused, in vitro fertilized embryos that are three to five days old. The embryos are only donated for research purposes with the informed consent of the donors. Embryonic stem cells are pluripotent, which means they can turn into any cell type in the body.

Adult stem cells are found in small numbers in developed tissues in different parts of the body, such as bone marrow, skin, and the brain. They are specific to a certain kind of tissue in the body and are limited to maintaining and repairing the tissue in which they are found. For example, liver stem cells can only make new liver tissue; they arent able to make new muscle tissue.

Induced pluripotent stem cells are another form of adult stem cells. These are stem cells that have been manipulated in a laboratory and reprogrammed to work like embryotic (or pluripotent) stem cells. While these altered adult stem cells dont appear to be clinically different from embryonic stem cells, research is still being conducted to determine if the effects they have on humans differ from actual embryonic stem cells.

Stem cells can also be found in amniotic fluid and umbilical cord blood. These stem cells have the ability to change into specialized cells like embryonic stem cells. While more research is being conducted to determine the potential of these types of stem cells, researchers already actively use these through amniocentesis procedures. In this procedure, the stem cells drawn from amniotic fluid samples of pregnant women can be screened for developmental abnormalities in a fetus.

How stem cells function

The main difference between embryonic and adult stem cells is how they function. Embryonic stem cells are more versatile. Since they can divide into more stem cells or become any type of cell in the body, they can be used to regenerate or repair a variety of diseased tissue and organs. Adult stem cells only generate the types of cells from where they are taken from in the body.

The future of stem cell research

The ability for stem cells to regenerate under the right conditions in the body or in a laboratory is why researchers and doctors have become so interested in studying them. Stem cell research is helping scientists and doctors to better understand how certain diseases occur, how to possibly generate healthy cells to replace diseased cells, and offer ways to test new drugs.

Clearly, stem cell research is showing great potential for understanding and treating a range of diseases and other health issues, but there is still a lot to learn. While there are some diseases that are showing success using stem cell treatments, many others are yet to be proven in clinical trials and should be considered highly experimental.

In our next article, various stem cell treatments, FDA regulations, and other stem cell hot topics will be explored. It will also focus on what to look for when considering stem cell therapies so people arent misled or misinformed about the benefits and risks.

For more information regarding the basics of stem cells visit these sites:

https://stemcells.nih.gov/info/basics/1.htm

https://www.mayoclinic.org/tests-procedures/bone-marrow-transplant/in-depth/stem-cells/art-20048117

Read more:
The 411 on Stem Cells: What They Are and Why It's Important to Be Educated - Legal Examiner

Will Cultured Meat Soon Be A Common Sight In Supermarkets Across The Globe? – Forbes

A hamburger made out of cell-based meat by Mosa Meat, one of many companies throughout the world ... [+] creating beef and other animal products without the animal.

Up until now, plant-based food companies like Beyond Meat, Impossible Foods, and Quorn have almost singlehandedly worked to lessen the impacts of industrial animal agriculture.

Supermarket shelves and fast food restaurants across the US are serving up vegan burgers and meatballs and plant-based chicken nuggets are showing consumers there is an alternative to relying on animal-based protein.

But a quiet revolution is also taking place in labs, where scientists are working to cultivate meat and seafood grown from cells, with the potential to reduce demand for industrial animal agriculture even further.

Heres how the process works: Stem cells are taken from the muscle of an animal, usually with a small biopsy under anesthesia, then theyre put with nutrients, salts, pH buffers, and growth factor and left to multiply. Finessing the technology and getting the cost to an affordable level is happening at a slower pace than the plant-based industry, but a number of start-ups are nevertheless aiming to get their products on the market soon.

Memphis Meats' pan-seared cell-based chicken with sugar snap peas.

Cell-based meat (also known as cultured, cultivated, slaughter-free, cell-cultured, and clean meat) will be a common sight in supermarkets across the west in the next three years, according to theInstitute of the Future in Palo Alto. California-based Memphis Meats made headlines for its world-first cell-based meatballs four years ago, and iscurrently building a pilot plantto produce its cultured beef, chicken, and duck on a bigger scale with plans to launch more plants around the world.

And it isnt the only cell-based meat start-up in the The Golden State. Theres the recently formed San Francisco-basedArtemys Foods, co-founded by biochemist Jess Krieger, who has spent the past six years working at Kent State University in Ohio growing cell-based meat in a lab, Berkeley-basedMission Barns, focusedon creating animal fat, which it has mixed with other ingredients to make duck sausages, and San Diego-based BlueNalu, a startup developing seafood from fish cells through a process called cellular aquaculture.

Close up of BlueNalu's whole-muscle, cell-based yellowtail, beer-battered and deep-fried for fish ... [+] tacos.

But innovation isnt limited to the US its happening across the world.The global cell-based meat market is predicted to be worth$15.5m by 2021 and $20m by 2027,according to analysis.One report estimates that35% of all meat will be cultured by 2040.

While estimates vary, one study found that cell-based beef is projected to use 95 per cent fewer global greenhouse gas emissions, 98 per cent less land use and up to half as much energy. It also significantly reduces the amount of antibiotics needed, which are widely used in agriculture and contribute hugely to worseningantibiotic resistance. And since the animal cells are extracted humanely and grown in a facility rather than within the animals themselves, cell-based meat has the potential to all but eliminate animal suffering.

The industry has made huge progress since the first cell-based hamburger was unveiled in 2013 in London byDutch stem cell researcher Mark Post, chief scientific officer atDutch companyMosa Meat.While this was a huge achievement, it also showed the world how far the industry had to go before commercially viable cell-based meat could be a reality. It cost $325,000 to make, and wasnt totally animal-free, as most of the burgers muscle strands were grown with fetal bovine serum, which comes from blood drawn from bovine fetuses.

In the intervening years, Mosa Meat has made several breakthroughs, and aims to bring the price down to a commercial price. It now doesnt require fetal bovine serum, and hasdeveloped a process thatallows industrial scale production.

Cell-based tartar (raw minced beef, commonly eaten in some of the Northern European countries), ... [+] created by Mosa Meat.

Also in the Netherlands, start-up Meatable has recently raised 9m to help reduce costs and scale-up production of its beef and pork. It aims to havean industry-scale plant by 2025,and will have a small-scale bioreactor the machine where cell-growth takes place - this year.Meatables cofounder Krijn de Nood hopes tounveil its first prototype this summer.

Elsewhere in Europe, the UKs Higher Steaks is growing stem cells for the production of mince for pork sausages. Instead of using fetal bovine serum,the company uses protocols exclusively licensed to itby its collaborators, the University of Minnesota, that allow it to reprogram stem cells into muscle and fat tissues.

Instead of adult stem cells, it uses induced pluripotent stem cells, which means they have an infinite supply as the cells proliferate infinitely. With adult stem cells, researchers have to go to the animal every time they need a new batch.

AndSpains Cubiq Foodsis producing cell-based fat, which is used to enhance the flavor of food and enrich it with essential fatty acids, such as omega-3.

But when it comes to cell-based meat, all eyes are on Israel, where a number of start-ups likeFuture Meat Technologies and SuperMeat are making huge progress. The countrys interest in cell-based meat has also been attributed to its thriving vegan culture.

Comparison of Future Meat Technologies' cell-based chicken (left) to of farm-raised chicken (right). ... [+]

Future Meat Technologies, founded in 2018, has shortened the manufacturing process to two weeks, with a patent-pending method they say allows for higher production yields of cell-based beef. The start-up's technologies enable producers, farmers and retailers to manufacture biomass and process it locally. The company hopes toget cost down to $10 per poundby 2022.

As for SuperMeat, it is developing cell-based meat from chicken cells (it claimed during its launch in 2016 that it wasthe first company to work on clean chicken productsfor mass production). One of Europe's largest poultry producers,PHW-Gruppe formed a partnershipwith SuperMeat in 2018. We believe 2020 will be the tipping point for the cultivated meat industry, once the proof of scale will be introduced to the world, says Shir Friedman, Co-Founder and Chief Communications Officer of the company. SuperMeat is excited to take a lead part in this historical event."

An illustration of SuperMeat's cell-based meat cultivators of the future.

Another Israeli start-up,Aleph Farms, created the worlds first cell-based steak at the end of 2018.It was co-founded only one year prior together with The Kitchen Hub from the Strauss Group, and with Professor Shulamit Levenberg of the Technion Institute of Technology. And in fall of 2019,Aleph Farmssuccessfully3D printedmeat on the International Space Station. Our experiment ofbioprintingmeat in space... consisted of printing a small-scale muscle tissue using 3D Bioprinting Solutions bioprinting technology, says Yoav Reisler, External Relations Manager for the company. The proof of concept sought to assess the potential of producing cultivated meat in a zero-gravity environment away from land and local water resources. Our approach for cultivating beef steaks is imperative to the experiment, as it relies on mirroring the natural process of tissue regeneration that happens in a cows body but under controlled and animal-free conditions. Our overarching goal is to produce meat products that have a significantly reduced ecological impact and this was a milestone in towards achieving that. Earlier this month, Aleph Farms announced plans to open an educational complex next to its production facility to provide the general public a more in-depth view of how cell-based meat is grown.

Thin-cut beef steaks cultivated by Aleph Farms.

Also in Israel,BioFood Systemsaims to produce beef products using bovine embryonic stem cells. It also hopes to scale up technology that it can license globally toenable meatmanufacturers to produce their own cell-based meat.

But other parts of the world arent far behind Israel, including Asia. Singaporean Shiok Meats is working on bringing cell-based based crustaceans (shrimp, crab and lobster) to market, and says its the first company of its kind in Singapore and South-East Asia. It hopes to have a commercially viable product in the next few years, and is currently researching and developing.

Shiok Meats cell-grown shrimp dumplings.

And in Japan, meat producer Toriyama and its export agent, Awano Food Group has partnered with JUST to grow, distribute and sell its cell-based wagyu beef worldwide.

JUST doesn't yet have images of its cell-based wagyu because its still in early stage R&D, but it ... [+] may one day look like this animal-based piece of Wagyu beef steak seen here.

In-between Asia and Europe, innovation is also happing in Turkey. Biftek is the first and still the only companydeveloping cultured meat in the country. It uses a plant-based formulation, made up of 44 proteins, in place of fetal bovine serum. Founder Can Akcali said in a recent interview that the media in Turkey is showing a growing interest in its work, and cell-based meat more widely.

Since the first cell-based unveiling of a cell-based burger in 2013, scientists have been flocking to labs in a race to iron out numerous teething problems and be the first to make a commercially viable cell-based meat product. Meanwhile, private investment into the industry has soared. Last year, twelve companiesraised $50 million in 14 deals double the amount of 2018. US-based Memphis Meats raised $22 million, Spain's Cubiq Foods raised $14 million and Mosa Meat drew in $9 million.

Memphis Meats now plans to build a pilot production facility,thanks to additional investments in January this yearfrom Cargill and Tyson Foods, as well as high-profile investors Bill Gates, Richard Branson, and Kimbal Musk.

Ido Savir, SuperMeats chief executive, said Mosa Meat introduced the concept of cell-based meat to the world, and that the main challenge start-ups are still facing is proof of scaling up production to a commercially viable size that's cost-efficient. Once these hurdles are overcome, it will be a much smoother process to get cell-based meat on shelves. At the moment, cell-based products are being prototyped in labs - but once scientists have finessed the process and the cost, theyre produced at scale and can grow in facilities like any other food.

Many cell-based start-ups expect to get their products to market in the next few years. Whether or not they are actually able to meet that projection is an open question. I worry most startups in the cultured meat space are overestimating their short-term timeline to get to market and underestimating their potential long-term impact on completely redesigning our food system from the cell-level up, says Max Elder, Research Director in the Food Futures Lab at Institute for the Future. Regardless of the timeline, one thing is clear: we desperately need to undo the damage industrialized animal agriculture is wreaking on our communities, animal, and planet. While it may indeed be unwise to count our cultured chickens before they hatch, especially in light of the urgent challenges we are facing, we can no doubt expect more innovation in the coming years. Perhaps one day - even if not in the near future - all the meat on our plates will indeed be slaughter-free.

Read this article:
Will Cultured Meat Soon Be A Common Sight In Supermarkets Across The Globe? - Forbes

Stem Cells Market Report by Manufacturers, Regions, Type and Application Forecast 2020-2025, Trends, Proportions, Share and SWOT. – Chronicle 99

The Report titled: Global Stem Cells Market Analysis: Production, Capacity, Sales, Revenue, Trends, Revenue Share, and Forecast till 2025

The authors of the Stem Cells Market Report have done extensive study of the global Stem Cells market keeping in mind the key aspects such as growth determinants, opportunities, challenges, restraints, and market developments. This analysis will enrich the ability of the companies involved in the global Stem Cells market to make precise decisions. The report also emphasizes on the current and future trends in the global Stem Cells market, which may bode well for the global Stem Cells market in the coming years.

The Stem cells are the cells found in the umbilical cord blood. These cells are being used in treating a wide range of conditions like sickle cell disease, leukaemia, and multiple myeloma. Birth of the child is the only chance to collect and store these valuable stem cells, which can be used to treat over 80 diseases. The Global Stem Cells Market was 5.21 Billion USD in 2018 and is estimated to reach 9.55Billion USD by 2025 at a CAGR of 9.04% during the forecast period

Get Free Exclusive Sample of this Premium Report at @ https://www.esherpamarketreports.com/request-sample/es-14599/

Table of Contents:1. Research Methodology2. Executive Summary3. Market Overview3.1. Definition3.2. Industry Value Chain Analysis3.3. Porters 5 Forces3.4. Regulations4. Market Dynamics4.1. Introduction4.2. Drivers4.3. Constraints4.4. Trends5. Global Stem Cells Market Segmentation, Forecasts and Trends by Product Type5.1. Adult Stem Cells5.2. Human Embryonic Stem Cells5.3. Induced Pluripotent Stem Cells5.4. Others6. Global Stem Cells Market Segmentation, Forecasts and Trends by Source6.1. Autologous6.2. Allogeneic7. Global Stem Cells Market Segmentation, Forecasts and Trends by Application7.1. Regenerative Medicine7.2. Drug Discovery & Development

Click Here For Detailed Table Of Contents

Enquire before purchasing this report @ https://www.esherpamarketreports.com/pre-order-enquiry/es-14599

Key Highlights of Stem Cells Market Report:

Reasons To Buy:

Purchase this Report with Full Access @ https://www.esherpamarketreports.com/purchase/es-14599/

Contact Us:

Name: Jason George

Email: sales@esherpamarketreports.com

Call :USA: +1 408 757 0510

Organization: eSherpa Market Reports

About Us:

eSherpa Market Reports is a credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed to optimizing your business. The reports we provide are based on research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.

Read this article:
Stem Cells Market Report by Manufacturers, Regions, Type and Application Forecast 2020-2025, Trends, Proportions, Share and SWOT. - Chronicle 99

Genetic Secrets of How a Strange Marine Animal Produces Unlimited Eggs and Sperm Over Its Lifetime – SciTechDaily

Piwi1-positive spermatogonia are shown in yellow; cell nuclei are in turquoise. Germ cell induction and all stages of gametogenesis can be visualized in these clonal animals. Credit: Timothy DuBuc, Ph.D. Swarthmore College

National Human Genome Research Institute-supported research of Hydractinia could provide clues to human reproductive conditions.

A little-known ocean-dwelling creature most commonly found growing on dead hermit crab shells may sound like an unlikely study subject for researchers, but this animal has a rare ability it can make eggs and sperm for the duration of its lifetime. This animal, called Hydractinia, does so because it produces germ cells, which are precursors to eggs and sperm, nonstop throughout its life. Studying this unique ability could provide insight into the development of human reproductive system and the formation of reproductive-based conditions and diseases in humans.

By sequencing and studying the genomes of simpler organisms that are easier to manipulate in the lab, we have been able to tease out important insights regarding the biology underlying germ cell fate determination knowledge that may ultimately help us better understand the processes underlying reproductive disorders in humans, Dr. Andy Baxevanis, director of the National Human Genome Research Institutes (NHGRI) Computational Genomics Unit and co-author of the paper. NHGRI is part of the National Institutes of Health.

Piwi1-positive oocytes are shown in yellow; cell nuclei are in turquoise. Germ cell induction and all stages of gametogenesis can be visualized in these clonal animals. Credit: Timothy DuBuc, Ph.D. Swarthmore College

In a study published in the journal Science, collaborators at NHGRI, the National University of Ireland, Galway, and the Whitney Laboratory for Marine Bioscience at the University of Florida, Augustine, reported that activation of the gene Tfap2 in adult stem cells in Hydractinia can turn those cells into germ cells in a cycle that can repeat endlessly.

In comparison, humans and most other mammals generate a specific number of germ cells only once in their lifetime. Therefore, for such species, eggs and sperm from the predetermined number of germ cells may be formed over a long period of time, but their amount is restricted. An international team of researchers have been studying Hydractinias genome to understand how it comes by this special reproductive ability.

Hydractinia lives in colonies and is closely related to jellyfish and corals. Although Hydractinia is dissimilar to humans physiologically, its genome contains a surprisingly large number of genes that are like human disease genes, making it a useful animal model for studying questions related to human biology and health.

Hydractinia colonies possess feeding polyps and sexual polyps as a part of their anatomy. The specialized sexual polyps produce eggs and sperm, making them functionally similar to gonads in species like humans.

Timing of germ cell formation in Hydractinia versus most animals. Credit: Timothy DuBuc, Ph.D. Swarthmore College

During human embryonic development, a small pool of germ cells that will eventually become gametes is set aside, and all sperm or eggs that humans produce during their lives are the descendants of those original few germ cells. Loss of these germ cells for any reason results in sterility, as humans do not have the ability to replenish their original pool of germ cells.

In a separate study, Dr. Baxevanis at NHGRI and Dr. Christine Schnitzler at the Whitney Lab have completed the first-ever sequencing of the Hydractinia genome. In this study, researchers used this information to scrutinize the organisms genome for clues as to why there are such marked differences in reproductive capacity between one of our most distant animal relatives and ourselves.

Having this kind of high-quality, whole-genome sequence data in hand allowed us to quickly narrow down the search for the specific gene or genes that tell Hydractinias stem cells to become germ cells, said Dr. Baxevanis.

The researchers compared the behavior of genes in the feeding and sexual structures of Hydractinia. They found that the Tfap2 gene was much more active in the sexual polyps than in the feeding polyps in both males and females. This was a clue that the gene might be important in generating germ cells.

The scientists next confirmed that Tfap2 was indeed the switch that controls the process of perpetual germ cell production. The researchers used the CRISPR-Cas9 gene-editing technique to remove Tfap2 from Hydractinia and measured the resulting effects on germ cell production. They found that removing Tfap2 from Hydractinia stops germ cells from forming, bolstering the theory that Tfap2 controls the process.

The researchers also wanted to know if Tfap2 was influencing specific cells to turn into germ cells. Their analysis revealed that Tfap2 only causes adult stem cells in Hydractinia to turn into germ cells.

Interestingly, the Tfap2 gene also regulates germ cell production in humans, in addition to its involvement in myriad other processes. However, in humans, the germ cells are separated from non-germ cells early in development. Still, despite the vast evolutionary distance between Hydractinia and humans, both share a key gene that changes stem cells into germ cells.

Reference: Transcription factor AP2 controls cnidarian germ cell induction by Timothy Q. DuBuc, Christine E. Schnitzler, Eleni Chrysostomou, Emma T. McMahon, Febrimarsa, James M. Gahan, Tara Buggie, Sebastian G. Gornik, Shirley Hanley, Sofia N. Barreira, Paul Gonzalez, Andreas D. Baxevanis and Uri Frank, 14 February 2020, Science.DOI: 10.1126/science.aay6782

This article describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose and treat disease. Science is an unpredictable and incremental process each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge of fundamental basic research.

The National Human Genome Research Institute (NHGRI) is one of the 27 institutes and centers at the NIH, an agency of the Department of Health and Human Services. The NHGRI Division of Intramural Research develops and implements technology to understand, diagnose and treat genomic and genetic diseases.

Original post:
Genetic Secrets of How a Strange Marine Animal Produces Unlimited Eggs and Sperm Over Its Lifetime - SciTechDaily

Embryonic Stem Cells

By: Ian Murnaghan BSc (hons), MSc - Updated: 8 Feb 2019| *Discuss

Embryonic stem cells have generated an enormous amount of ethical controversy and discussion, primarily because of their source. As the name implies, embryonic stem cells are derived from embryos. As with all stem cells, embryonic stem cells are unspecialised cells that have the ability to:

The embryonic stem cells are usually derived from in vitro fertilisation, where the eggs have been fertilised in vitro (not in a woman's body) and donated for research with donor consent. The embryos are generally utilised when they are approximately four or five days old and constitute a tiny ball of cells known as a blastocyst. Pluripotent embryonic stem cells are derived from the blastocyst. Embryonic stem cells can, however, be either totipotent or pluripotent cells. Those cells that are totipotent include the fertilised egg itself as well as the cells produced during the very early divisions. These totipotent embryonic stem cells have the ability to become any cell in the human body. Pluripotent stem cells, on the other hand, can become any type of cell in the body except those needed to develop a foetus.

Research on embryonic stem cells can also improve the safety of drugs. By testing drugs on embryonic stem cell lines, scientists can gauge their safety before testing them further in laboratory animals and human subjects. Also beneficial would be the knowledge of precisely how embryonic stem cells differentiate and proliferate. Many serious medical conditions such as cancer and birth defects result from dysfunctional cell replication and specialisation. If researchers can learn exactly what happens during normal healthy cell development, they can better understand what happens to lead to disease.

Embryonic stem cells are certainly a promising discovery, but their use will likely not become consistent and approved until procedures for isolating and growing them are proven and defined. A lack of widespread public acceptance also clouds the therapeutic use of embryonic stem cells but hopefully, the concerns and challenges can be overcome in the future so that those suffering from serious diseases can benefit from embryonic stem cells.

You might also like...

Share Your Story, Join the Discussion or Seek Advice..

Sarah - 5-Nov-15 @ 1:20 AM

Hope - 20-May-15 @ 12:22 AM

tezza - 22-May-12 @ 10:43 AM

Title:

(never shown)

Originally posted here:
Embryonic Stem Cells